Grand Hyatt Hotel, New York City 2012 | November 28-30

Grand Hyatt Hotel, New York City 

2012 | November 28-30

AdvAnce your r&d 

objectives through 

P4c connect! 

P4C Connect helps you find nontraditional 

allies—like leaders from nonprofits foundations, 

academic institutions, and philanthropic 

organizations—who can help you advance 

your R&D goals. 

• review Profiles of other P4c PArticiPAnts. 

• schedule one-on-one And/or grouP meetings. 

• build your customized P4c schedule—from 

PAnels to PresentAtions to PArtnering 

meetings—And sync it with your cAlendAr 

of choice. 

It also allows you to request free, private, 

25-minute advice sessions on: 

• strAtegic PlAnning 

• AttrActing cAPitAl 

• collAborAtion structuring 

• interActing with the fdA 

• communicAtions & mArketing 

Get the mobile P4C Connect app: P4C Connect is accessible via your 

iPhone, iPad, or Android Device. You can download it from the 

iTunes App Store, Google Play Store, or scan the QR codes here. 

iPhone Android 

All partnering meetings are held in Ballrooms 1 and 5.

TABLE OF CONTENTS 

Welcome Letters ............................................................................................................................. 3 

Hotel Map .......................................................................................................................................................6 

Program & Activities ..................................................................................................................................7 

Panelists .........................................................................................................................................................36 

Expert Consultations .............................................................................................................................. 81 

Sponsors ........................................................................................................................................................96 

Supporters .................................................................................................................................................108 

Milken Institute Strategic Partners ...............................................................................................109 

Staff ................................................................................................................................................ 111 

Acknowledgments ................................................................................................................................114

Welcome to Partnering for cures! 

Now in its fourth year, this meeting continues to build momentum and harness energy because it attracts 

hundreds of leaders from across sectors of the medical research enterprise who are getting things done. 

We have designed the Partnering for Cures experience to facilitate cross-sector collaborations and 

solutions sharing that are needed to speed up the time it takes to turn discoveries into therapies. 

It features 16 dynamic, outcomes-focused discussions including those about how social media is 

changing research norms, how the results of election 2012 will impact medical research, and how 

insurers are impacting the research and innovation agenda, just to name a few. 

We will hear presentations from 30 innovators in cross-sector collaboration—from Janssen R&D to 

the Mayo Clinic, from Lawrence Livermore National Lab to the Myelin Repair Foundation, and many, 

many more—describing their efforts to commercialize early-stage discoveries, share data, develop 

novel research tools, repurpose assets, and create innovative financial models to drive progress. 

And this year, we are featuring P4C Connect, a partnering system customized with your needs in mind. 

Participants—from innovators to investors, philanthropists to industry executives, federal officials to 

scientists—will have concrete opportunities to find nontraditional allies who can help advance critical 

research and development goals. Through P4C Connect, you can also request private consultation sessions 

with 25 leading experts who are available to provide free advice on a variety of commonly faced issues 

including strategic planning, collaboration structuring, attracting capital, interacting with the FDA, 

and communications and marketing. 

We know the realities all too well: the pathway to treatments and cures is littered with failure, lack of funding, 

scientific and regulatory challenges, reimbursement issues, healthcare delivery issues, the daunting list 

goes on. But, we also know that by working together, we can break down these barriers and speed up 

the time it takes to turn discoveries into treatments and cures. That’s what brings us here today. 

Enjoy the meeting! 

Sincerely, 

Margaret Anderson 

Executive Director 

FasterCures 

Michael L. Klowden 

President and CEO 

Milken Institute 

welcome letter 3

T H E C I T Y O F N E W Y ORK 

O FFI C E O F T H E M A Y O R 

T H E C I T Y O F N E W Y ORK 

N E W Y O R K , N Y 1 0 007 

O FFI C E O F T H E M A Y O R 

N E W Y O R K , N Y 1 0 007 

November 28, 2012 

November 28, 2012 

Dear Friends: 

Dear Friends: 

It is a great pleasure to welcome everyone to the Partnering for Cures conference, hosted 

by FasterCures, 

It is a great 

the 

pleasure 

Milken 

to 

Institute’s 

welcome 

Center 

everyone 

for Accelerating 

to the Partnering 

Medical 

for Cures 

Solutions. 

conference, hosted 

by FasterCures, the Milken Institute’s Center for Accelerating Medical Solutions. 

Our Administration takes its responsibility to help New Yorkers protect and improve 

their health 

Our 

and 

Administration 

the health of 

takes 

their 

its 

families 

responsibility 

very seriously. 

to help New 

Thanks 

Yorkers 

to our 

protect 

innovative 

and improve 

public 

their 

health 

health 

agenda 

and 

and 

the 

our 

health 

efforts 

of their 

to reduce 

families 

non-communicable 

very seriously. Thanks 

diseases 

to 

like 

our 

diabetes, 

innovative 

heart 

public 

disease, 

and 

health 

cancer, 

agenda 

our 

and 

residents 

our efforts 

are living 

to reduce 

longer 

non-communicable 

than ever before. 

diseases 

We are 

like 

proud 

diabetes, 

of the progress 

heart disease, 

we 

and 

have 

cancer, 

made, 

our 

but there 

residents 

is still 

are 

work 

living 

to 

longer 

be done. 

than 

Since 

ever 

its 

before. 

establishment, 

We are proud 

FasterCures 

of the progress 

has worked 

we 

to 

have 

improve 

made, 

the 

but 

medical 

there 

research 

is still work 

system 

to be 

and 

done. 

accelerate 

Since its 

the 

establishment, 

development of 

FasterCures 

new therapies 

has 

for 

worked 

a wide 

to 

improve 

range of diseases, 

the medical 

many 

research 

of which 

system 

currently 

and accelerate 

have few 

the 

available 

development 

treatments. 

of new 

This 

therapies 

week’s 

for a wide 

conference 

range of diseases, 

will facilitate 

many of 

industry 

which currently 

partnerships 

have 

that 

few 

will 

available 

help more 

treatments. 

quickly connect 

This week’s 

patients with 

conference 

the innovative 

will 

medicines 

facilitate industry 

they need, 

partnerships 

and we applaud 

that will 

FasterCures 

help more 

for 

quickly 

its unwavering 

connect patients with 

the 

commitment 

innovative 

to 

medicines 

improving 

they 

health 

need, 

care 

and 

for 

we 

us 

applaud 

all. 

FasterCures for its unwavering 

commitment to improving health care for us all. 

On behalf of all New Yorkers, I offer my best wishes for a productive conference and 

continued 

On 

success. 

behalf of all New Yorkers, I offer my best wishes for a productive conference and 

continued success. 

Sincerely, 

Sincerely, 

Michael R. Bloomberg 

Michael 

Mayor 

R. Bloomberg 

Mayor 

welcome letter 5

6 

Empire V 

Ballroom Level 

Palace 

Conference Level 

Lobby Level 

finding your Way around 

Wintergarden 

Front Desk 

1 

Concierge 

Elevators 

Registration 

Elevators 

Alvin Broadway 

Uris 

Elevators 

42nd St. entrance 

Partnering 

Help Desk 

Empire Ballroom Empire I 

Partnering for Cures event rooms are in white 

Majestic 

Shubert 

1. Ambassador 2. Orpheum 3. Gershwin 

2 

3 

Booth 

Imperial 

Morosco 

Plymouth 

Royale

program 

& activities

8 

Wednesday 

november 28, 2012 

6:00 PM - 8:00 PM EmpirE BALLrOOm FOyEr 

Registration 

6:30 PM - 8:00 PM EmpirE BALLrOOm FOyEr 

Welcome Reception 

ThuRsday 

november 29, 2012 

7:00 AM - 7:00 PM EmpirE BALLrOOm FOyEr 

Registration 

7:00 AM - 7:50 AM EmpirE BALLrOOm 

Continental Breakfast (featuring Therapeutic affinity and Building 

Block Roundtables) 


Welcome and Opening Remarks 

Margaret anderson, Executive Director, FasterCures


Opening Plenary 

The (Near) Future of Bioscience and Health 

Our collective investment, public and private, in biomedical science over the last several decades has reaped 

enormous benefits for the health and well-being of society, in the U.S. and globally. Many believe we’re on the 

brink of even greater achievements built on our growing understanding of human biology. What are some 

of the most amazing discoveries coming from academic labs with government and industry funding? 

What entrepreneurial new approaches are being taken to move these discoveries into the marketplace? 

What is the promise for patients, and how are they becoming an even greater force for change? This panel 

will make a forceful case for not only continuing but accelerating our collective efforts. 

Speakers: 

Mikael dolsten, President, Worldwide Research and Development, Pfizer 

Jay schnitzer, Director, Defense Sciences Office, Defense Advanced Research Projects Agency (DARPA) 

Vicki seyFert-Margolis, Senior Advisor, Science Innovation and Policy, Office of the Commissioner, 

U.S. Food and Drug Administration (FDA) 

Moderator: 

Michael Milken, Chairman, Milken Institute; Founder, FasterCures 

9:15 AM - 11:40 AM EmpirE BALLrOOm i ANd V 

Partnering and expert Consultations 

program & activities 9 

thursday

10 

BREAKOUT PANEL 


9:15 AM - 10:10 AM BrOAdwAy 

Optimists Only: Is Life Sciences Still a Good Investment? 

The much-lamented “VC retreat” from early-stage life sciences financing has created both a gap and an 

opportunity. While some investors have notably exited the field, new players have emerged, including 

corporate VCs, public-private partnerships, venture philanthropies, even sovereign wealth funds. This panel 

will bring together investors of all stripes who remain optimistic about the field and passionate about the 

need to apply innovative financial and operational models to finding and funding science that holds the 

promise of helping patients. Why invest now? How should investors be thinking about and measuring their 

return? What makes the life sciences an attractive field when compared to social media or IT? For those who 

are exiting the space, what might compel them to come back? 

Speakers: 

Jens eckstein, President, SR One 

dan hartMan, Director, Integrated Development, Bill and Melinda Gates Foundation 

garen staglin, Co-Founder, One Mind for Research 

alastair J.J. Wood, Partner, Symphony Capital 

Moderator: 

chris VarMa, President and CEO, Blueprint Medicines 

9:15 AM - 10:10 AM ALViN/CArNEgiE 

Social Media Changing Research Norms 

As more scientists take their work to the Web and the cloud – publishing papers in open-access journals, 

recruiting trial participants through Facebook, and crowd-sourcing investigations – the availability and 

traction of social media tools to support medical research have grown. Facilitating everything from the 

establishment of “virtual lab space” to the crowd-funding of promising science/scientists, these networks 

are gaining traction in an increasingly collaborative research environment. Panelists will highlight popular 

networking sites/tools and preview what’s next for patients and researchers. 

Speakers: 

Jon Fredrickson, Vice President, Government Practice, Innocentive 

elizabeth iorns, Co-Founder and CEO, Science Exchange 

sally okun, Health Data Integrity Manager, PatientsLikeMe 

greg siMon, CEO, Poliwogg 

John Wilbanks, Senior Fellow, Ewing Marion Kauffman Foundation 

Moderator: 

MattheW herPer, Senior Editor, Forbes Magazine


INNOvATOR PREsENTATION 

9:15 AM - 10:10 AM UriS/JULLiArd 

License to Drive (Innovation): IP Strategies to Support, Not Slow, Progress 

Intellectual property (IP) protection is critical to driving investment in new products that can help patients 

as well as create economic value. Some maintain that IP protection can make more challenging scientific 

collaboration, technology transfer, and commercialization. This panel will explore the evolving IP law and 

procedures; the IP implications of the movement toward more precompetitive collaboration in biology; 

examples of responsible IP management practices; and how IP decisions can impact follow-on innovation 

and patient access. What role can government and philanthropic funders play in setting the stage for 

responsible IP negotiation and management? How will patent reform and implementation of the America 

Invents Act impact innovators in the life science industry? Is it possible to create an agreed-upon culture 

of responsibility and incentivize players to adhere to it? 

Speakers: 

JosePh desiMone, Director, Frank Hawkins Kenan Institute of Private Enterprise, and Professor of Chemistry, UNC 

stePhen Friend, President, Sage Bionetworks 

stePhen Johnson, Partner, Kirkland & Ellis LLP 

teresa stanek rea, Deputy Director, U.S. Patent and Trademark Office 

steVen tregay, Founder, President, and CEO, FORMA Therapeutics 

Moderator: 

Maria Freire, President, Foundation for the NIH 

10:15 AM – 10:40 AM BrOAdwAy 

Clinical Trials Transformation Initiative 

The Clinical Trials Transformation Initiative (CTTI) is a public-private partnership, co-founded by FDA 

and Duke University, to identify practices that through broad adoption will increase the quality and 

efficiency of clinical trials. CTTI engages all stakeholders whose involvement is critical for transformation 

to occur in clinical trial conduct. To accomplish its mission, CTTI conducts projects aimed at making 

incremental improvements to the current system and at shaping clinical trials of the future. Results and 

recommendations of these projects help to inform regulatory policies, as well as the practices of those 

who conduct trials. 

Presented by: 

robert caliFF, Professor of Cardiology, Vice Chancellor for Clinical Research, and Director of the Duke 

Translational Medicine Institute, Duke University School of Medicine 

bray Patrick lake, Director of Stakeholder Engagement, Clinical Trials Transformation Initiative 


thursday

12 



10:15 AM – 10:40 AM ALViN/CArNEgiE 

ImproveCareNow Collaborative Chronic Care Network 

The ImproveCareNow Network’s purpose is to transform the health, care, and costs for all children and 

adolescents with inflammatory bowel disease (IBD) by building a sustainable collaborative chronic care 

network, enabling patients, families, clinicians, and researchers to work together in a learning healthcare 

system to accelerate innovation, discovery, and the application of new knowledge. The 46 U.S. and U.K. sites 

include a population-based registry (more than 14,000 patients), more than 25 percent of U.S. pediatric 

gastrointestinal specialists, families, researchers, and innovators. The network has increased the proportion 

of children and adolescents with IBD in remission from 55 percent to 76 percent, without new medications. 

Presented by: 

Peter Margolis, Professor of Pediatrics and Director of Research, James M. Anderson Center for Health 

Systems Excellence, Cincinnati Children’s Hospital Medical Center, University of Cincinnati School of Medicine; 

Scientific Director, ImproveCareNow Network 

richard colletti, Professor of Pediatrics and Vice Chair, Department of Pediatrics, University of Vermont 

School of Medicine; Network Director, ImproveCareNow Network 

10:15 AM – 10:40 AM UriS/JULLiArd 

CIMIT CoLab 

Effective collaborations across disciplines, groups, and institutions are critical to stimulating and accelerating 

innovations to patient care. But, too often, a lack of consistency and/or experience undermine otherwise 

promising projects. The Center for Medicine and Innovative Technology (CIMIT) CoLab is a secure, cloudbased, 

configurable, Enterprise 2.0 platform focused on streamlining the many needed collaborative 

processes, such as document curation, knowledge management, and workflow automation. The CoLab 

is eager to engage healthcare providers, universities, foundations, and other nonprofits to benefit from 

and also improve its ability to leverage the vast experience, insight, and innovative talents of staff, faculty, 

industry partners, advisors, and patients in accelerating the healthcare innovation cycle. 

Presented by: 

John M. collins, Chief Operating Officer, The Center for Medicine and Innovative Technology 

Vinit niJhaWan, Managing Director, Technology Development Office, Lecturer, School of Management, 

and Director, Enterprise Programs, ITEC Boston University




Code-N: A Silicon Valley Life Sciences “Big Data” Start-up 

A major challenge to developing “faster cures” is that key information about compounds, proteins, genes, 

and diseases is spread over dozens of databases. The goal of the Open Pharmacological Space initiative 

is to integrate industry data sources via “Concept Web” semantic technology to provide a data hub for 

researchers. Code-N’s mission is to empower scientists to analyze all relevant data simultaneously 

“in the cloud” to make compound-gene-protein-disease connections that are not feasible today. Code-N will 

highlight its first product, the Green Field Finder, and demonstrate how this new technology can help 

researchers find “green fields” of opportunity to cure diseases faster. 

Presented by: 

randy haldeMan, CEO, Code-N 

Marketta silVera, Founder/Executive Chairman, Code-N 


Alzheimer’s Association: Advancing Alzheimer’s Research Through 

Whole Genome Sequencing 

A unique collaboration between the Alzheimer’s Association, the Brin Wojcicki Foundation, and the 

Alzheimer’s Disease Neuroimaging Initiative (ADNI) was formed with the goal to obtain whole genome 

sequences on the largest cohort of individuals related to a single disease, Alzheimer’s disease. The project 

has potentially groundbreaking importance due to the ability to match highly-robust Alzheimer’s biomarker 

data from ADNI with newly generated gene sequence data. Completed sequences will be freely shared to 

qualified scientists around the globe to mine for novel targets for risk assessment, new therapies, 

and much-needed insight into the causes of this devastating brain disease. 

Presented by: 

dean hartley, Director of Science Initiatives, Alzheimer’s Association 


thursday

14 




Harrington Project for Discovery and Development 

The Harrington Project for Discovery and Development is a $250 million national initiative to support the 

discovery and development of breakthrough therapeutics by physician-scientists. Through an aligned 

set of mission-driven entities, the project is a new and open-system model for advancing medicine. 

Presented by: 

Jonathan s. staMler, Co-Leader, The Harrington Project for Discovery & Development; Director, UH 

Harrington Discovery Institute, University Hospitals Case Medical Center and Case Western Reserve University 

baiJu r. shah, Co-Leader, The Harrington Project for Discovery & Development; CEO, BioMotiv 


Sage Bionetworks: BRIDGE 

BRIDGE is an open source online platform intended to leverage the revolution in medical data collection 

technologies so that research questions posted on BRIDGE from the public can trigger the collection of 

citizen-patient data (molecular and self-reported). These data are shared and worked on by researchers 

through open projects and community challenges. The results will catalyze basic medical research and also 

help to identify those citizen-patients most likely to respond to a certain medicine, and those who are in 

need of medicines that have yet to be developed. 

Presented by: 

stePhen h. Friend, President, Co-Founder, and Director, Sage Bionetworks




TREAT-NMD Advisory Committee for Therapeutics 

TREAT-NMD Advisory Committee for Therapeutics (TACT) provides the neuromuscular community 

(clinicians, researchers, patient advocacy groups, and industry) with a unique resource of world-class 

multidisciplinary experts offering independent and objective guidance on advancing potential therapies 

(novel or repurposed) for neuromuscular diseases. The goal of each review is to position the candidate 

compound along a realistic and well-informed pathway to clinical trials and eventual registration. 

TACT is unique in that its review is not conducted with the goal of making a funding decision, but rather 

as an independent drug development review service that’s accessible to advocacy and funding 

organizations, such as Parent Project Muscular Dystrophy. 

Presented by: 

cristina csiMMa, Chair, TREAT-NMD Advisory Committee for Therapeutics 

sharon hesterlee, Senior Director of Research and Advocacy, Parent Project Muscular Dystrophy 


Massachusetts General Hospital: Vaccine and Immunotherapy Center 

The Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital seeks to accelerate the 

development of innovative new technologies with broad applicability to the treatment and prevention 

of cancer and infectious diseases in the U.S. and beyond. The center’s approach is to leverage and apply 

the collective experience and expertise of medical and business professionals to promising candidates in 

academic research in order to accomplish critical tasks required to successfully translate them from the 

preclinical to the clinical stage of development, and to transition them from academic laboratories into 

appropriate companies and other organizations. VIC has seven technologies in its pipeline. 

Presented by: 

Mark c. Poznansky, Director, Vaccine and Immunotherapy Center, Associate Professor, 

Harvard Medical School, Massachusetts General Hospital 

tiMothy brauns, Associate Director, Vaccine and Immunotherapy Center, Massachusetts General Hospital 


thursday

16 

12:00 PM - 1:30 PM EmpirE BALLrOOm 

Luncheon Plenary 

What You Probably Don’t Know About Innovation at FDA 

The U.S. Food & Drug Administration is frequently criticized for being a significant barrier to innovation, 

accused of being slow and unpredictable in its reviews and approvals. But most people, even within the 

pharmaceutical industry, are probably unaware of the many efforts in which FDA is engaged in trying to 

smooth and speed the drug development process. From qualification of new drug development tools to 

mining the mountains of data in its possession, FDA is working with partners in a variety of ways to improve 

the process from the earliest days of research. This session will review some of those efforts, evaluate their 

success thus far, and consider what further efforts are needed to improve FDA’s ability to review the innovations 

coming through the development pipeline. 

Speakers: 

JosePh degeorge, Global Head of Safety Assessment, Merck Research Laboratories 

Frank l. douglas, President and CEO, Austen BioInnovation Institute 

richard a. insel, Chief Scientific Officer, JDRF 

Jonathan leFF, Managing Director, Warburg Pincus 

Janet Woodcock, Director, Center for Drug Evaluation and Research, U.S. Food and Drug Administration 

Moderator: 

Margaret anderson, Executive Director, FasterCures 

1:45 PM - 6:00 PM EmpirE BALLrOOm i ANd V 

Partnering and expert Consultations



1:45 PM – 2:10 PM BrOAdwAy 

Jonah’s Just Begun/Phoenix Nest: Disrupting Drug Discovery 

Jonah Weishaar has a rare disease called Sanfilippo Syndrome (MPSIIIC). Jill Wood formed Jonah’s Just Begun 

(JJB) to fund research into the disease and to help other families. Since Partnering for Cures 2011, JJB has 

helped get language included in the Prescription Drug User Fee Act, formed a company, Phoenix Nest, Inc. 

(PN) to commercialize treatments for MPSIIIC, and submitted a Small Business Innovation Research proposal 

to fund PN research. JJB has co-authored a white paper on a generalized approach for orphan diseases 

and has developed a mobile app to raise awareness and share drug discovery data. This presentation will 

highlight what is possible in a year to disrupt the drug discovery process. 

Presented by: 

Jill Wood, Treasurer, Jonah’s Just Begun, and CEO, Phoenix Nest, Inc. 

sean ekins, CSO, Phoenix Nest, Inc. 

1:45 PM – 2:10 PM ALViN/CArNEgiE 

Lawrence Livermore National Laboratory: Heart Modeling 

Predictive multi-physics modeling and simulation of the whole human heart on the world’s highest 

performance supercomputer promises to accelerate new discoveries and innovation in cardiology, 

cardiovascular disease, pharmacology, and patient-specific therapies. The presenters will discuss results 

of ongoing collaboration with IBM Research into cardiac dysfunction and anti-arrhythmia drug effects 

with cellular level visibility, along with other transformative partnering opportunities for biotech and 

pharmaceutical companies that offer proprietary, on-demand access to computational expertise and 

highly scalable codes running on high-performance computers. 

Presented by: 

Fred streitz, Director, Institute for Scientific Computing Research, Lawrence Livermore National Laboratory 

JeFF WolF, Chief Business Development Officer, HPC Innovation Center, Lawrence Livermore National Laboratory 


thursday

18 



1:45 PM – 2:10 PM UriS/JULLiArd 

DART Therapeutics 

DART Therapeutics, LLC is an innovative, new model biotech designed to address the challenges of drug 

development in pediatric rare diseases. DART is a partnership between patient foundations and industry 

professionals. It is funded by two patient associations in Duchenne Muscular Dystrophy (Charley’s Fund 

and Nash Avery), and is managed by a team of seasoned industry professionals. Since presenting at 

Partnering for Cures in 2010, DART has acquired numerous therapeutic assets, completed a biomarker 

validation study that will benefit the entire DMD community, and expanded the management team. 

The DART model is a promising new way to navigate the “valley of death.” 

Presented by: 

gene WilliaMs, Chairman and CEO, DART Therapeutics, LLC 


Life Raft Group: GIST Collaborative Tissue Bank 

Fresh, frozen tissue, which is difficult to come by, as it is collected at the time of surgery, is considered to 

be the standard for patient tissue study. Formalin-fixed, paraffin-embedded tissue is much easier to access 

and use for large-scale studies, but is limited as a model for research testing. The Life Raft Group utilizes 

both methods of tissue collection in order to get the most benefit from the tissue. The presenter will explain 

the tissue process in detail and how it is transformative, collaborative, and employs de-identified patient 

histories to further enhance research findings. 

Presented by: 

norMan J. scherzer, Executive Director, The Life Raft Group




Mayo Clinic, Todd and Karen Wanek Family Program for Hypoplastic 

Left Heart Syndrome 

Nearly 2,000 infants are born each year with Hypoplastic Left Heart Syndrome and require immediate 

surgical intervention – these children remain at risk for a heart transplant throughout their lives. The Todd 

and Karen Wanek Family Program for Hypoplastic Left Heart Syndrome (HLHS) is a purpose-driven operation 

forged within an academic medical environment that is designed to accelerate idealism into practice. 

This entity emerged out of the Mayo Clinic, dedicated participation of HLHS patients and families, and the 

focused milestone-based vision of its philanthropic partner. The principle objective of the program is to 

delay or prevent heart transplant by applying functional regenerative strategies for children with HLHS. 

Presented by: 

tiMothy J. nelson, Director of Regenerative Medicine Consult Service, Transplant Center, 

Director of the Todd and Karen Wanek Family Program for Hypoplastic Left Heart Syndrome, Mayo Clinic 

Mindy rice, Program Manager, Todd and Karen Wanek Family Program for Hypoplastic Left Heart Syndrome, 

Mayo Clinic 


Immusoft 

Immusoft’s ISP platform turns a patient’s own cells into drug factories that can secrete therapeutic proteins, 

such as lysosomal enzymes, in vivo. It can facilitate the rapid creation and deployment of new treatments 

simply by changing a plasmid in a vector, which eliminates common production and delivery challenges. 

The ISP platform can be used by Immusoft or others to treat diseases too rare to be addressed by current 

technologies in an economically viable manner. Immusoft is seeking to identify unmet medical needs that 

can be addressed with its platform and connect with collaborators to treat these diseases. 

Presented by: 

MattheW scholz, CEO, Immusoft 


thursday

20 




Multiple Myeloma Research Foundation/Genospace 

The Multiple Myeloma Research Foundation (MMRF) and its Personalized Medicine Initiative Consortium 

launched the CoMMpass Study to map 1,000 myeloma genomes. Genospace provides IT services and 

bioinformatics expertise, including computational workflows and networked communities, on a single 

platform. The MMRF-Genospace partnership unifies comprehensive longitudinal clinical and genomic 

data with expert bioinformatics tools and social networking to drive data access and knowledge building 

insights to patients, collaborators, and the public. The project’s common goal is to increase access, promote 

discovery, and expedite development of drugs, diagnostics, and clinical trials. Its collaborative model 

shortens the timelines to access, analyze, share, and translate important findings into the clinic. 

Presented by: 

carolyn hoban, Director of Translational Research, Multiple Myeloma Research Foundation 

Mick correll, Co-Founder and Chief Operating Officer, Genospace 


KNODE, Inc. 

Efficiently drawing on the appropriate internal and external subject matter expertise is essential to drive 

transformative discovery and translational medicine initiatives, yet no comprehensive approach exists. 

Working closely with AstraZeneca and other syndicate partners, Enlight Biosciences founded KNODE to 

fundamentally alter the experience of finding and collaborating with experts. KNODE’s novel, cloud-based 

software platform enables a variety of innovation efforts through the advanced identification of life sciences 

experts and their content. This collaboration supports the development of KNODE’s global knowledgebase, 

with the end result being a platform to support partnership development in AstraZeneca’s core therapeutic 

areas of high unmet need. 

Presented by: 

baruch harris, Chief Business Officer, Enlight Biosciences 

daVid tharP, Head of Business Development, KNODE, Inc.




iValue: The Biological Pacemaker 

Columbia University is developing a biological pacemaker for human use, offering a cure, rather than the 

palliation provided by electronic pacemakers, for heart arrhythmia. It uses encapsulated stem cells transfected 

with the pacemaking gene, which is a path-breaking approach to the treatment of disease. The presenting 

organization has assembled an intellectual property portfolio of a dozen essential patents and know-how 

on related nanotechnology; a consortium of top U.S. and E.U. scientists/clinicians, including access to clinical 

trial facilities; government grants from an E.U. country; and executives with U.S. FDA and European regulatory 

experience. Its approach is highly capital efficient and applies the concept of open innovation. 

Presented by: 

c. WilleM houck, CEO, i-Value UAB and Managing Director, i-Value LLC 


Accelerated Cure Project for Multiple Sclerosis: OPT-UP Study 

Optimizing Treatment–Understanding Progression (OPT-UP) is a multi-center, longitudinal clinical study 

coupled with partnership-based analyses of biosamples and data and development of tools and assays. 

Its aim is to transform the treatment of multiple sclerosis (MS) in two important ways: (1) Optimizing Treatment: 

The prospect of controlling MS has never been better, with several therapies approved and others to come. 

Carefully gathered evidence will allow the project to help people with MS choose the treatment that is optimal 

and safe for them. (2) Understanding Progression: Determine the mechanisms underlying progressive disease 

in MS, which is unresponsive to current therapies and causes significant disability. 

Presented by: 

hollie schMidt, VP of Scientific Operations, Accelerated Cure Project for Multiple Sclerosis 


thursday

22 




tranSMART Foundation 

tranSMART is a global open source community using and evolving a data sharing and analysis platform 

to accelerate clinical and translational research. The tranSMART community includes pharmaceutical and 

for-profit companies, nonprofit, academic, patient advocacy, and government stakeholders. The tranSMART 

value proposition relies on its members, who are the best source of innovation. The tranSMART Foundation 

will convene private and public stakeholders to 1) set scientific, data, analytics, and platform priorities; 2) secure 

long-term sustainable funding; and 3) coordinate with European Union (ETRIKS, IMI 5-year, €24 million) 

and US-based initiatives through lightweight, transparent governance, outreach, and engagement. 

Presented by: 

brian d. athey, Collegiate Professor and Chair, Department of Computational Medicine and Bioinformatics, 

University of Michigan Medical School 

Michael braxenthaler, President, Pistoia Alliance 


Janssen Research & Development: Circulating Tumor Cells Collaboration 

Veridex, LLC and Massachusetts General Hospital, along with Janssen Research & Development, 

are collaborating to develop and commercialize a next-generation circulating tumor cell technology 

for capturing, counting, and characterizing tumor cells found in patients’ blood. The partnership focuses 

on the development of a system that will enable CTCs to be used both by oncologists as a diagnostic tool 

for personalizing patient care, as well as by researchers to accelerate and improve the process of drug 

discovery and development. This collaboration is an opportunity to advance a platform that will benefit 

patients facing a devastating cancer diagnosis.


3:45 PM - 4:40 PM BrOAdwAy 

Beyond Business as Usual: Disrupting the Biopharma Business Model 

“Disruptive innovation” is all the rage in the business community, and the term is catching on in the 

biopharmaceutical industry, which may be the industry currently most in need of disrupting. But who 

is doing anything that might truly disrupt the biopharma business model, rather than just improving 

on how things are done now? Are we seeing the “dis-integration” of the pharmaceutical industry? 

Are there new players, new partnerships, new roles to be filled? 

Speakers: 

kathy giusti, Founder and CEO, Multiple Myeloma Research Foundation 

bernard Munos, Chief Apostle, Breakthrough Innovation, InnoThink 

steVen Marc Paul, Director, Helen & Robert Appel Institute for Alzheimer’s Research, Weill Cornell Medical College 

toMasz sablinski, Founder, Transparency Life Sciences; Head of Development, Celtic Therapeutics 

ben shaPiro, Senior Partner and Chairman of the Board, PureTech Ventures 

Moderator: 

gautaM Jaggi, Global Lead Analyst, Editor, Beyond Borders and Progressions, 

EY Knowledge/Global Life Sciences Center 


thursday

24 


3:45 PM - 4:40 PM ALViN/CArNEgiE 

The Health Network Trust: Improving Innovation, Outcomes, 

and Efficiency in Healthcare 

We hear a lot these days about how data sharing and collaboration have great potential to reduce the cost 

of healthcare and improve outcomes for patients – but who is actually doing it? What is at stake, what are the 

barriers, and what are potentially scalable solutions? This panel will provide a case example of a patient-centric 

demonstration project within the ImproveCareNow Network, which includes 44 pediatric gastrointestinal 

care centers and more than 13,000 patients and has succeeded in improving remission rates by sharing best 

practices between care teams across sites. The demonstration project will deploy a technology backbone 

allowing for the efficient flow of data and a novel IP framework to enable cross-sector collaboration; 

participants include entrepreneurs, patients, physicians, designers, researchers, payers, psychologists, parents, 

community leaders, and technologists. 

Speakers: 

John chaFFins, Director, Product Design & Construction, Lybba 

richard colletti, Professor of Pediatrics and Vice Chair, Department of Pediatrics, University of Vermont 

School of Medicine; Network Director, ImproveCareNow Network 

anMol Madan, Co-founder, CEO, and Data Scientist, Ginger.io 

Peter Margolis, Professor of Pediatrics and Director of Research, James M. Anderson Center for Health Systems 

Excellence, Cincinnati Children’s Hospital Medical Center, University of Cincinnati School of Medicine; 

Scientific Director, ImproveCareNow Network 

John Wilbanks, Senior Fellow, Ewing Marion Kauffman Foundation 

Moderator: 

doMinique Pahud, Director, Advancing Innovation, Kauffman Foundation


3:45 PM - 4:40 PM UriS/JULLiArd 

Can Clinical Trials Be Better, Faster, and Cheaper? 

It’s impossible to talk about “faster cures” without talking about significantly reducing the time and cost 

of the clinical trials process. The challenges are well known, and many solutions have been proposed, 

but “transformation” has been elusive. This panel will discuss current innovations that could feed such 

systems change, including new trial models (such as adaptive trial designs, point-of-care studies, 

“clinical trials in a box”); better use of technologies for data collection and analysis as well as patient 

screening and recruitment (including mobile technology and electronic health records); and critical 

business process improvements such as reducing site monitoring and data validation costs and study 

start-up costs. 

Speakers: 

robert caliFF, Professor of Cardiology, Vice Chancellor for Clinical Research, and Director of the Duke 


cliFFord a. hudis, Chief, Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center; 

President-elect, American Society of Clinical Oncology 

laWrence J. lesko, Professor of Pharmaceutics, Director, Center for Pharmacometrics 

and Systems Pharmacology, University of Florida 

garry neil, Partner, Apple Tree Partners 

susan soloMon, CEO and Co-Founder, New York Stem Cell Foundation 

Moderator: 

Melissa steVens, Deputy Executive Director, FasterCures 

5:00 PM – 7:00 PM mEzzANiNE LEVEL 

Reception 


thursday

26 

FRiday 

november 30, 2012 

7:00 AM - 3:00 PM EmpirE BALLrOOm FOyEr 

Registration 


Continental Breakfast (featuring Therapeutic affinity 

and Building Block Roundtables) 


Opening Remarks 


Morning Plenary 

Molecule to Man (and Woman): Speeding Translation to Human Trials 

Our national investment in basic science is producing dividends as measured by the thousands of promising new 

discoveries that now need to move through the translational research process and into humans. Between the new 

National Center for Advancing Translational Sciences and the Cures Acceleration Network at NIH, and multiple 

novel financing and operational experiments taking place in academia and industry, the translational train has 

left the station. What are the next big innovations coming out of this effort that can help us get to human clinical 

trials faster? How can we better identify and fix failures in the process of moving compounds from animal models 

to humans? Can systems biology help? How can we accelerate development and regulatory pathways to proof of 

concept? What can be done to improve the reproducibility of results? 

Speakers: 

chris austin, Director, National Center for Advancing Translational Sciences, National Institutes of Health 

anna barker, Director, Transformative Healthcare Networks, Co-Director, Complex Adaptive Systems Initiative 

and Professor, School of Life Sciences, Arizona State University 

dale edgar, Lilly Distinguished Research Fellow, Global Head, Science and Technology Partnerships, LRL 

stelios PaPadoPoulos, Co-Founder and Chairman, Exelixis 

todd sherer, CEO, The Michael J. Fox Foundation for Parkinson’s Research 

Moderator: 

Margaret anderson, Executive Director, FasterCures



9:15 AM - 10:10 AM ALViN/CArNEgiE 

Tech Transfer 2.0: Innovation in University Commercialization 

There is a growing realization that the traditional model of technology transfer at universities isn’t entirely 

keeping up with the growing complexity and changing landscape of biomedical research and development. 

Though agreement structures are still evolving and funding sources are changing, a growing appetite for 

earlier information sharing and partnering have led to new and creative approaches to collaboration. 

What do these models look like? Can they be replicated? How can we incentivize a continued focus on 

advancing basic scientific discovery while at the same time supporting early-stage development? 

Speakers: 

louis berneMan, Founding Partner, Osage University Partners 

Jodi black, Deputy Director, Division of Extramural Research Activities, NHLBI, NIH 

chris coburn, Executive Director, Cleveland Clinic Innovations 

regis b. kelly, Director, The California Institute for Quantitative Biosciences (QB3), University of California 

robert urban, Head, Cambridge Innovation Center, Johnson & Johnson 

Moderator: 

lou degennaro, Chief Mission Officer, Leukemia and Lymphoma Society 

9:15 AM - 10:10 AM UriS/JULLiArd 

Rules, Tools, and Data Pools for Catalyzing Drug Development 

The semiconductor industry created the SEMATECH consortium in the 1980s in response to a perceived 

existential threat to the industry. Many would say the pharmaceutical industry is facing a similar crisis 

today. SEMATECH came together with government to solve common problems by leveraging resources and 

sharing risks. Today there are many efforts under way to create drug development tools – from therapeutic 

area data standards to preclinical safety biomarkers to patient-reported outcomes instruments – needed by 

the field, involving the pre-competitive sharing of data and expertise, and leading to the development of 

standards that are then qualified by FDA and other regulatory bodies. What are some of those efforts? Are they 

sufficient, and are they sufficiently unified? What are the barriers to accomplishing more? If appropriate 

infrastructures are in place, what questions do we want to ask of the data generated and gathered? 

Speakers: 

dana ball, CEO and Co-Founder, T1D Exchange 

Marc bonneFoi, Head, North America R&D Hub, Sanofi US 

carolyn coMPton, President and CEO, Critical Path Institute 

eric d. Perakslis, Chief Information Officer and Chief Scientist (Informatics), U.S. Food and Drug Administration 

george Vradenburg, Chairman, USAgainstAlzheimer’s 

Moderator: 

brett daVis, Senior Director, Health Sciences Global Business Development and Strategy, Oracle 


Friday

28 



9:15 AM - 10:10 AM BrOAdwAy 

He Who Pays, Eats: The Evolving Role of Payers in The R&D Ecosystem 

Payers, including the federal Centers for Medicare and Medicaid Services, are taking an increasingly visible 

seat at the R&D table, long before they get asked to pick up the tab. They’re mining their vast databases 

and partnering with pharmaceutical companies to help them develop more personalized medicines faster. 

What’s coming next? Is it possible we’ll see a future where payers reimburse only for drugs proven to work 

in certain populations? Will they co-sponsor clinical trials and share risk with developers? Could such 

collaboration revive waning investor confidence? How can we ensure the incentives of all the stakeholders 

are aligning to the greatest extent possible – and that the interests of patients remain the centerpiece? 

Speakers: 

Mark cziraky, Co-founder and Vice President, Industry Sponsored Research, HealthCore 

shari ling, Deputy Chief Medical Officer, Centers for Medicare & Medicaid Services 

kiM J. PoPoVits, President and CEO, Genomic Health, Inc. 

russell teagarden, Former Vice President, Scientific Affairs, Advanced Clinical Science and Research, 

Medco Health Solutions, Inc. 

Moderator: 

ceci connolly, Managing Director, Health Research Institute, PricewaterhouseCoopers 


Sanofi / Michael J. Fox Foundation for Parkinson’s Research 

In the spirit of developing new and creative research collaborations to speed up delivery of effective 

therapies for patients, the Michael J. Fox Foundation for Parkinson’s Research (MJFF) and Sanofi are 

collaborating to explore the potential use of a dormant Sanofi compound, AVE8112, in the treatment 

of Parkinson’s disease. Trial results will be owned by MJFF and shared with Sanofi. This is an excellent 

example of a novel approach to enhancing our collective ability to tackle complex diseases. 

Presented by: 

Marc bonneFoi, Head of the North America R&D Hub and Vice President of Disposition, 

Safety and Animal Research Scientific Core Platform, Sanofi 

todd sherer, CEO, Michael J. Fox Foundation for Parkinson’s Research




Rare Genomics Institute: Collaborative Crowdsourced Prize Competitions 

to Accelerate Research 

Increasingly, prize competitions are used as a tool to leverage an entire community of researchers to work 

on scientific challenges and solve problems. The Rare Genomics Institute has partnered with over 25 different 

organizations to launch campaigns to accelerate rare diseases - with the prize amount totaling over $700,000. 

Partners have included academia, industry, media, nonprofits, and patient advocacy groups, among others. 

In the context of campaigns, such as the Rare99X Clinical Exome Sequencing Challenge and the BeHEARD 

Rare Disease Science Challenge, we will describe our experience, challenges, lessons learned, and future 

plans – and perhaps even create new partnerships at the conference. 

Presented by: 

JiMMy lin, Founder and President, Rare Genomics Institute 

keVin lustig, President and CEO, The Assay Depot, Inc. 


Myelin Repair Foundation: Translational Medicine Center 

The Myelin Repair Foundation’s Accelerated Research Collaboration (ARC) model is designed to optimize 

the entire therapeutics development continuum through collaboration, for multiple sclerosis and all diseases. 

As part of the ARC model, the Myelin Repair Foundation’s Translational Medicine Platform evaluates promising 

therapeutics to identify potential drug candidates for successful clinical trials. Recently, the foundation’s own 

Translational Medicine Center was established, a world-class laboratory led by foundation scientists with 

extensive biopharma experience bringing compounds into the clinic. The foundation establishes a new 

paradigm for medical research, leveraging its position as a non-partisan entity to develop new therapeutics 

to meet patient need. 

Presented by: 

scott Johnson, CEO, President, and Founder of the Myelin Repair Foundation 


Friday

30 




CFIDS Association of America / Biovista 

The collaboration between the CFIDS Association of America and Biovista leverages the accumulated 

knowledgebase for chronic fatigue syndrome (CFS) and state-of-the-art approaches to data synthesis and 

analysis. The partners seek to identify novel drug candidates based on published data and patient-reported 

data collected under the association’s SolveCFS BioBank using Biovista’s proprietary Clinical Outcome Search 

Space drug repurposing platform. Harnessing this information and the unique subject expertise of these 

two organizations, the partners aim to expeditiously identify a set of repurposing candidates ready to test 

as mono- or multi-therapy trials with a solid, biology-based rationale for reducing symptoms and addressing 

the underlying pathophysiology of CFS. 

Presented by: 

aris Persidis, President & Co-Founder, Biovista 

suzanne d. Vernon, Scientific Director, The CFIDS Association of America 


Crohn’s & Colitis Foundation of Canada/Vertex 

The Crohn’s and Colitis Foundation of Canada/Vertex Sponsored Research Program represents a unique 

business model in that both a nonprofit organization and a biotech are providing joint funding 

to early-stage discovery research being conducted at several leading academic centers across Canada. 

The three-year collaboration includes two rounds of grant funding to fund novel research aimed at 

identifying the underlying disease mechanisms and drivers of Inflammatory Bowel Disease (IBD). 

This joint investment to better understand the underlying biology of IBD has the potential to lead to 

better and expedited treatments for patients living with IBD. 

Presented by: 

keVin glasgoW, CEO, Crohn’s and Colitis Foundation of Canada 

yousseF bennani, Vice-President, Research & Development, Vertex Pharmaceuticals




The Nicholas Conor Institute: CURE Partners 

CURE Partners is an initiative of The Nicholas Conor Institute that ushers promising discoveries made by the 

childhood cancer research community into clinical development. Through CURE Partners, foundations will 

fulfill their mission by delivering childhood cancer cures to the clinic, giving survivors long, healthy lives. 

Leukemia & Lymphoma Society’s Therapy Acceleration Program is a successful strategic initiative that serves 

as a model for singling out sponsored research discoveries, creating development strategies, and forming 

corporate partnerships to advance them in the clinic. CURE Partners will accelerate, develop, and deploy new 

cancer treatments for children, adolescents, and young adults. 

Presented by: 

beth anne baber, Co-Founder and CEO, The Nicholas Conor Institute 

lou J. degennaro, Chief Mission Officer, Leukemia and Lymphoma Society 


Critical Path Institute: Critical Path to TB Drug Regimens 

The Critical Path to TB Drug Regimens (CPTR) is a public-private partnership working to advance the 

development of safer, more effective and faster-acting combination therapies for tuberculosis (TB). 

Worldwide, there are an estimated 8.8 million new cases of TB each year, and 1.4 million people die from 

this disease every year. The current first-line TB treatment is five decades old and must be taken for at least 

six months. CPTR is developing the innovative regulatory science with a strong component of translational 

pharmacology, essential for supporting new combination drug development through the CPTR Regulatory 

Science Consortium, led by the Critical Path Institute. 

Presented by: 

klaus roMero, Director of Clinical Pharmacology, Critical Path Institute 


Friday

32 




NCI SBIR Investor Forum 

The National Cancer Institute (NCI) Small Business Innovation Research (SBIR) Investor Forum brings together 

government and industry to accelerate the commercialization of innovative cancer-related technologies. 

The Investor Forum advances government-funded innovations toward the patient by connecting investors 

with companies validated through NCI SBIR/Small Business Technology Transfer funding and forum 

selection. The 2012 forum enabled 18 selected companies to present to more than 150 potential investors 

and was the venue for more than 100 one-on-one meetings. Seven of the 14 presenting companies at the 

2010 forum have secured deals worth $235 million from relationships established at the event. The forums 

demonstrate the transformative opportunity for the government to facilitate follow-on investments in 

funded technologies. 

Presented by: 

todd haiM, Program Director, NCI SBIR Development Center 


New York Genome Center: Collaboration for Life 

Genomics will fundamentally change healthcare. It impacts the entire disease detection, diagnosis, 

treatment, and prevention spectrum. The use of sequencing data, coupled with the power of bioinformatics, 

will accelerate drug development, greatly enhance the efficiency of R&D expenditures, and enable physicians 

to provide the right treatments, to the right targeted patient populations, at the right price, in the right time. 

The New York Genome Center has harnessed the power of 11 major academic medical and research centers, 

along with world-class bioscience and technology companies, to create an exciting new research and 

innovation paradigm that will transform science and healthcare. 

Presented by: 

nancy J. kelley, Founding Executive Director, New York Genome Center



11:45 AM - 12:40 PM BrOAdwAy 

Election 2012: What Does it Mean for Medical Research? 

This panel will focus on the implications of the outcomes of the November elections for biomedical research 

and innovation. What will happen to funding for science in an era of constrained federal and state budgets? 

How will efforts to reign in healthcare costs – with or without the Affordable Care Act – impact medical 

innovation? How will economic policy issues influence the direction of the biopharma industry? What initiatives 

should the new administration and Congress pursue in order to support biomedical innovation and leadership 

in the U.S.? 

Speakers: 

scott gottlieb, Resident Fellow, American Enterprise Institute 

cheryl Jaeger, Science Policy Advisor, Majority House Leadership, U.S. House of Representatives 

Wendell PriMus, Senior Health Policy Advisor, Minority House Leadership, U.S. House of Representatives 

neera tanden, President and CEO, Center for American Progress; Counselor, Center for American 

Progress Action Fund 

11:45 AM - 12:40 PM ALViN/CArNEgiE 

Basic Science: The More We Know, the More We Know What We don’t Know 

There is a growing sense not only in academia but also in industry that in many therapeutic areas of medical 

research we simply don’t know enough about the basic biology of disease to effectively pursue treatments 

for them. Drug development in therapeutic areas such as HIV/AIDS and Alzheimer’s have been brought up 

short by a sense that we may be shooting in the dark at unclear targets – that we’re wasting ammunition, 

so to speak. What are some of the gaping holes in our understanding of basic biology that are preventing 

us from more effectively developing treatments? What is the appropriate balance between the pursuit of 

fundamental science and the pursuit of treatments? Can we do both at the same time more effectively? 

Speakers: 

WilliaM chin, Executive Dean for Research, Harvard Medical School 

thoMas r. insel, Director, National Institute of Mental Health, National Institutes of Health 

robert ring, Vice President, Translational Research, Autism Speaks 

Jonathan siMons, President and CEO, Prostate Cancer Foundation 

Matthias Von herrath, Director, Type 1 Diabetes Research and Development Center, Novo Nordisk 

Moderator: 

cecilia arradaza, Director, Communications & Marketing, FasterCures 


Friday

34 


11:45 AM - 12:40 PM UriS/JULLiArd 

Molecular Diagnostics: Turning on the Lights 

With the elucidation of the human genome and the revolution in molecular biology technologies, we are 

increasingly capable of monitoring human biology and disease in very sophisticated ways. Our ability 

to measure biological processes and indicators is now essentially “turning on the lights” on our ability to 

understand how life works. But tests using molecular methods, including molecular diagnostics, are the 

rate-limiting step for the full promise of personalized medicine to be realized. Challenges include the 

development of viable business models and the lack of reimbursement policies that recognize the value 

of companion diagnostics. In addition, laboratory-developed tests are being used extensively, but not 

always with proper validation, and FDA is struggling to provide regulatory guidelines that address this 

issue without stifling innovation. What are the components of a thoughtful strategy for incorporating 

high-quality, validated molecular testing into the development and delivery of targeted health interventions? 

Speakers: 

daVid Parkinson, Venture Partner, New Enterprise Associate 

Michael Pellini, President and CEO, Foundation Medicine 

JeFFrey trent, President and Research Director, The Translational Genomics Research Institute 

sean tunis, Director, Center for Medical Technology Policy 

Moderator: 

Wendy selig, President and CEO, Melanoma Research Alliance

1:00 PM - 2:30 PM EmpirE BALLrOOm 

Luncheon Plenary 

Powered by Patients 

Lately it seems that drug developers and media alike are awakening to the profound impact of patients and patient 

organizations in driving the direction of medical research. Frustrated by the lack of options and armed with 

a unique understanding of the challenges, these foot-soldiers for cures are taking their fight from the bedside 

to the lab – funding high-risk, high-reward research projects, finding and fostering scientific expertise, and shifting 

the perception of patients as advocates to patients as participants. This panel will address lessons in patient 

participation – how to find and engage them before you need their help, what they’re doing to speed medical 

progress in their diseases, and what you can learn from their pioneering efforts. 

Speakers: 

bonnie J. addario, Founder & Chair, President, The Bonnie J. Addario Lung Cancer Foundation 

n. anthony coles, President, CEO, and Member of the Board, Onyx Pharmaceuticals 

Francis collins, Director, National Institutes of Health 

scott Johnson, President, CEO, and Founder, Myelin Repair Foundation 

dennis urbaniak, Vice President, U.S. Diabetes, Sanofi US 

Moderator: 

susan dentzer, Editor-in-Chief, Health Affairs 

2:45 PM - 4:40 PM EmpirE BALLrOOm i ANd V 

Partnering and expert Consultations 


Friday

panelists

BOnnie J. addaRiO 

Founder & Chair, President, The Bonnie J. Addario Lung Cancer Foundation 

Bonnie J. Addario is an eight-year lung cancer survivor. Two foundations for lung cancer 

were formed after Addario discovered the dismal survival rate of this disease to be only 

15.9 percent. Bonnie J. Addario Lung Cancer Foundation and the Addario Lung Cancer 

Medical Institute work together for great change. Her experience as a patient, an executive 

with a San Francisco-based oil company, and as the first woman president on the board of the 

California Oil Marketer’s Association has been a catalyst to advancing the health of lung cancer 

patients because the current system is under great stress for funding and innovation. 

MaRgaReT andeRsOn 

Executive Director, FasterCures 

Margaret Anderson is executive director of FasterCures/The Center for Accelerating 

Medical Solutions, a Milken Institute center that works to speed up the timeline for new 

medicines to go from discovery to patients. In 2011, the Clinical Research Forum recognized 

her with an award for leadership in public advocacy. Anderson is president of the Alliance 

for a Stronger FDA, co-chairs the eHealth Initiative’s Council on Data and Research, and is 

a member of the National Center for Advancing Translational Sciences Advisory Council, 

the Cures Acceleration Network Review Board, the Prostate Cancer Foundation Government 

Affairs Committee, and the Institute of Medicine’s Forum on Drug Discovery, Development 

and Translation. Previously, Anderson was at the Academy for Educational Development, 

the Society for Women’s Health Research, the American Public Health Association, and the 

Congressional Office of Technology Assessment. She holds a bachelor’s degree from the 

University of Maryland and a master’s degree in science, technology, and public policy from 

George Washington University. 

panelists 37

38 

CeCiLia aRRadaza 

Director, Communications & Marketing, FasterCures 

Cecilia Arradaza is FasterCures’ communications & marketing director. She brings to 

FasterCures more than 15 years of experience in public relations, public affairs, and strategic 

communications on policy issues that impact medical research and the life sciences 

industry. She joined FasterCures from Chandler Chicco Agency (CCA), a pure-play health 

communications firm, where she developed public affairs programs for clients including 

Johnson & Johnson, the Robert Wood Johnson Foundation, and VHA Inc. Before joining 

CCA, Arradaza implemented strategic communications and issues management initiatives 

for pharmaceutical and foundation clients of Hyde Park Communications; managed media 

relations and public education efforts for the American Psychiatric Association; and was 

part of the health and international public affairs practices at Powell Tate. Arradaza began 

her health communications career at the National Osteoporosis Foundation and through 

an internship with the National Women’s Health Network. She received her bachelor’s 

degree from George Washington University at Mount Vernon College. 

ChRisTOPheR P. ausTin 

Director, National Center for Advancing Translational Sciences 

Chris Austin is the director of the National Center for Advancing Translational Sciences 

(NCATS) at the National Institutes of Health (NIH). Previously, he was NCATS’ director of 

pre-clinical innovation. Prior to that, Austin founded and led the National Center for 

Chemical Genomics at NIH, building it into one of the leading centers for high-throughput 

screening, chemical probe development, and chemical genomics. He also served as senior 

advisor to the director at the National Human Genome Research Institute. Prior to his time 

at NIH, Austin spent seven years at Merck, where he directed genomics-based research 

programs. He received his bachelor’s degree from Princeton University and his medical 

degree from Harvard University.

dana BaLL 

CEO and Co-Founder, T1D Exchange 

Dana Ball is the CEO and co-founder of T1D Exchange. He has been driving innovative 

diabetes initiatives for over 10 years. Most recently, Ball was program director for the 

Helmsley Type 1 Diabetes Program at the Leona M. and Harry B. Helmsley Charitable Trust. 

While there, he co-founded the T1D Exchange, which is a nonprofit research organization 

whose mission is to improve quality of life for people with type 1 diabetes. Prior to joining 

the Helmsley Charitable Trust, Ball served as executive director at the Iacocca Foundation, 

where he oversaw all aspects of the family’s charities and led a multimillion dollar public 

campaign to advance the emerging field of beta cell regeneration. Ball has been a patient 

advocate since the early 1980s, with broad advocacy experience in a wide range of serious 

diseases, including type 1 diabetes and HIV/AIDS. Ball received his degree in business 

administration from the University of Southern Maine. 

anna BaRkeR 

Director, Transformative Healthcare Networks, Co-Director, Complex Adaptive Systems Initiative 

and Professor, School of Life Sciences, Arizona State University 

Anna Barker is Arizona State University’s director of Transformative Healthcare Networks, 

co-director of the Complex Adaptive Systems Initiative, and professor in the School of Life 

Sciences. Prior to this position, Barker served as deputy director at the National Cancer 

Institute (NCI). While at NCI, Barker developed multi- and trans-disciplinary programs, 

including the Nanotechnology Alliance for Cancer, The Cancer Genome Atlas, Clinical 

Proteomics Technologies Initiative for Cancer, and a network of “Physical Sciences-Oncology 

Centers.” She also developed the Cancer Human Biobank and Cancer Bioinformatics Grid. 

Before NCI, Barker served at Battelle Memorial Institute for 18 years. Barker has received 

many awards, including being named in 2009 as one of “The 100 People Changing America” 

by Rolling Stone magazine. Barker completed her doctorate at The Ohio State University. 

panelists 39

40 

LOuis BeRneMan 

Founding Partner, Osage University Partners 

Louis Berneman founded Osage University Partners using his knowledge from years of 

experience managing university-level technology transfer offices. Berneman is also currently 

the principal of Texelerate, a technology transfer consultancy he formed in 2005 to assist 

academic institutions in monetizing their intellectual property assets. He is the former 

managing director of the Center for Technology Transfer of the University of Pennsylvania 

and the former director of licensing and business development for Virginia’s Center for 

Innovative Technology. He has been a founder, director, and/or president of several start-ups, 

including Biotherapeutics, Inc., InnoTech, and TMune Therapeutics. He received a master of arts, 

master of teaching, and doctorate in education from the Teachers College, Columbia University, 

a teaching credential from University of California, Santa Barbara, and a bachelor of arts in 

history from the Pennsylvania State University. 

JOdi BLaCk 

Deputy Director, Division of Extramural Research Activities, National Heart Lung 

and Blood Institute, National Institutes of Health 

As deputy director of the division of extramural research activities at the National Heart, 

Lung, and Blood Institute (NHLBI), Jodi Black leads and oversees all extramural research 

and training programs. At NHLBI, Black also serves as the acting director of the Office of 

Translational Alliances and Coordination, which provides leadership and coordination to 

accelerate the translation of basic discoveries and innovations into new diagnostics, devices, 

and therapeutics. Previously, she worked as vice president of research administration at the 

Translational Genomics Research Institute. She also held several positions at the National 

Cancer Institute. Black received her bachelor of arts from Rollins College and her doctorate 

from Emory University.

MaRC BOnneFOi 

Head, North America R&D Hub, Sanofi US 

Marc Bonnefoi is currently the head of the North America Research and Development Hub 

as well as vice president of Disposition, Safety and Animal Research Scientific Core Platform 

at Sanofi-Aventis (US). As the head of the North American R&D hub, his responsibilities include 

establishing and maintaining connections with North American public and private scientific 

organizations, in addition to identifying potential opportunities in terms of innovation and 

partnership. He oversees activities across North America. Prior to this role, he was Sanofi’s 

global head of drug safety evaluation, responsible for the nonclinical safety evaluation 

of all drug candidates. Bonnefoi earned his doctorate in both veterinary medicine and 

pharmacology from the University of Toulouse, France. 

ROBeRT CaLiFF 

Professor of Cardiology, Vice Chancellor for Clinical Research, and Director of the Duke 


Robert Califf is the Donald F. Fortin, MD, Professor of Cardiology, vice chancellor for clinical 

research, and director of the Duke Translational Medicine Institute. Califf has led some of 

the best-known clinical trials and health outcomes studies in cardiovascular medicine and 

has published more than 1,000 peer-reviewed original articles in collaboration with his 

colleagues. He is currently the seventh-most frequently cited author in the field of medicine 

globally. He has served on numerous committees and panels assisting in the development of 

health policy, including the Cardiorenal Panel of the FDA and multiple Institute of Medicine 

committees, including the Committee on Identifying and Preventing Medication Errors, 

the Forum on Drug Discovery and Translation, and the Science Board of the Food and Drug 

Administration. He was the founding director of the Coordinating Center for the Centers for 

Education and Research in Therapeutics, a public/private partnership focused on the safety of 

medical products. He received his medical degree from Duke University School of Medicine. 

panelists 41

42 

JOhn ChaFFins 

Director, Product Design & Construction, Lybba 

John Chaffins is the director of product design and construction at Lybba, a nonprofit that seeks 

to build an open-source health and learning network offering personalized medicine that is 

affordable and broadly available. Prior to joining Lybba, Chaffins served as chief information 

officer for the JFK Medical Center and worked as a physician systems consultant with Columbia/ 

HCA Healthcare. He completed an Interaction Design Practicum in communications design 

with Cooper University and attended Ohio State University, where he studied medical records 

administration and health information management. 

WiLLiaM Chin 

Executive Dean for Research, Harvard Medical School 

In May 2010, William W. Chin became the executive dean for research at Harvard Medical 

School. In this role, Chin leads the school’s research efforts, with special emphasis on 

interdisciplinary and translational research. Chin has been a faculty member at Harvard for 

25 years. He previously served as a professor of medicine, chief of the Division of Genetics, 

and senior physician at Brigham & Women’s Hospital, and an investigator at Howard Hughes 

Medical Institute. Prior to working in academia, Chin worked at Eli Lilly and Company for 

more than a decade. Chin’s research often focused on translational research - connecting 

basic laboratory discoveries to their medical relevance. Chin received his medical degree 

from Harvard Medical School.

ChRis COBuRn 

Executive Director, Cleveland Clinic Innovations 

Chris Coburn has served as the executive director of Cleveland Clinic Innovations (CCI) 

since it was established in May 2000. CCI is the Cleveland Clinic’s corporate venturing arm. 

Under Coburn’s leadership, CCI has raised more than $450 million in equity investment and, 

in June 2010, it was recognized by Global Corporate Venturing as one of the world’s top 30 

health corporate venturing organizations. He previously worked as vice president and general 

manager of Battelle Memorial Institute and director of the U.S. Enrichment Corporation. 

Coburn received his bachelor’s degree from John Carroll University and his master’s in public 

administration from George Washington University. 

n. anThOny COLes 

President, CEO, and Member of the Board, Onyx Pharmaceuticals 

N. Anthony Coles joined Onyx in March 2008 as president/CEO. Prior to Onyx, he served as 

president/CEO of NPS Pharmaceuticals. In 2002, he joined Vertex Pharmaceuticals as senior 

vice president, Commercial Operations. Between 1992 and 2002, he held executive level 

positions at Bristol-Myers Squibb and Merck & Co. Coles completed his cardiology and internal 

medicine training at Massachusetts General and was a research fellow at Harvard Medical. 

He earned a medical degree from Duke University, a master’s degree in public health from 

Harvard University, and a bachelor’s degree from Johns Hopkins University. Coles is a member 

of the boards of trustees for Johns Hopkins University and Johns Hopkins Medicine. He is a 

member of the boards of directors for Laboratory Corporation of America and Campus Crest 

Communities (both NYSE traded companies), and Biotechnology Industry Organization. 

panelists 43

44 

RiChaRd COLLeTTi 

Professor of Pediatrics and Vice Chair, Department of Pediatrics, 

University of Vermont School of Medicine 

Richard Colletti has been with the University of Vermont College of Medicine since 2003. 

He serves as professor of pediatrics and is vice chair in the Department of Pediatrics. 

He is also network director of the ImproveCareNowNetwork and holds multiple clinical 

appointments, including associate chief at the Vermont Children’s Hospital, founder and 

director of the Pediatric Lipid Disorders Clinic, and attending in pediatrics at the Medical 

Center Hospital of Vermont. He also has served as president of the North American Society 

for Gastroenterology, Hepatology and Nutrition. Colletti holds a medical degree from the 

University of Pittsburgh and a bachelor of arts in psychology from University College. 

FRanCis COLLins 

Director, National Institutes of Health 

Francis Collins is the director of the National Institutes of Health (NIH). In that role, he oversees 

the work of the largest supporter of biomedical research in the world, spanning the spectrum 

from basic to clinical research. Collins is a physician-geneticist noted for his landmark 

discoveries of disease genes and his leadership of the international Human Genome Project, 

which culminated in April 2003 with the completion of a finished sequence of the human DNA 

instruction book. He served as director of the National Human Genome Research Institute at 

NIH from 1993 to 2008. Before coming to NIH, Collins was a Howard Hughes Medical Institute 

investigator at the University of Michigan. He is an elected member of the Institute of Medicine 

and the National Academy of Sciences, was awarded the Presidential Medal of Freedom in 

2007, and received the National Medal of Science in 2009. Collins earned his bachelor’s degree 

in chemistry at the University of Virginia, his doctorate in physical chemistry at Yale University, 

and his medical degree from the University of North Carolina.

CaROLyn COMPTOn 

President and CEO, Critical Path Institute 

Carolyn Compton is the president and CEO of Critical Path Institute. She was most recently 

the director of the Office of Biorepositories and Biospecimen Research and the executive 

director of the Cancer Human Biobank project at the National Cancer Institute. She is also an 

adjunct professor of pathology at the Johns Hopkins School of Medicine. Compton received 

her medical degree from Harvard Medical School and doctorate from the Harvard Graduate 

School of Arts and Sciences. 

CeCi COnnOLLy 

Managing Director, Health Research Institute, PricewaterhouseCoopers 

Ceci Connolly is a nationally known healthcare consultant, speaker, author, and conference 

facilitator. She joined PricewaterhouseCoopers as the managing director of the Health Research 

Institute earlier this year. She currently specializes in assisting in the implementation of the 

Affordable Care Act. She has served as a contributing author for several books on America’s 

healthcare policies. Connolly is also a board member for the nonprofit Whitman Walker Health 

and is the first non-physician to receive the Mayo Clinic’s prestigious Plummer Society Award. 

She was formerly The Washington Post’s chief health policy correspondent and chronicled 

the battle over President Obama’s healthcare reform. Additionally, Connolly is an experienced 

speaker who has been praised for her ability to translate complex subjects for audiences at all 

levels. Connolly was the recipient of a fellowship at Harvard’s Kennedy School of Government 

and is a graduate of Boston College. 

panelists 45

46 

MaRk CziRaky 

Co-Founder and Vice President, Industry Sponsored Research, HealthCore 

Mark Cziraky is HealthCore’s co-founder and vice president of Industry Sponsored Research. 

Prior to starting HealthCore, Cziraky was an assistant professor of clinical pharmacy at 

The Philadelphia College of Pharmacy and Science. Accreditation Council for Clinical 

Lipidology accredited him as a Clinical Lipid Specialist, making him the first pharmacist to 

achieve that title in Pennsylvania and Delaware. He is also a member of NHLBI’s National High 

Blood Pressure Education Program Coordinating Committee, the board of the Institution of 

Safe Medication Practice, the American Pharmacists Association Foundation, and the National 

and Northeast Lipid. Cziraky also holds an adjunct associate professor appointment at the 

University of Delaware School of Nursing and a clinical faculty position at The University of 

Florida College of Pharmacy. Cziraky earned his bachelor and doctorate of pharmacy degrees 

from the Philadelphia College of Pharmacy and Science. 

BReTT davis 

Senior Director, Health Sciences, Global Business Development and Strategy, Oracle 

Brett Davis is a senior director in Oracle’s Health Sciences Global Business Unit. He is responsible 

for shaping and driving Oracle’s personalized healthcare strategy and solutions. Prior to joining 

Oracle, Davis was a business unit executive in IBM’s Healthcare and Life Sciences business, 

where he helped shape IBM’s strategy for health analytics, clinical genomics, high performance 

scientific computing, biobanking, and translational medicine. Davis sits on the board of the 

Personalized Medicine Coalition, is on the Health Resources and Services Administration’s 

Genetic Services Advisory Panel, and has been an invited speaker at industry meetings on 

information technology’s transformative role in the health sciences. Davis is a graduate of 

Pennsylvania State University.

LOu degennaRO 

Chief Mission Officer, Leukemia and Lymphoma Society 

Lou DeGennaro contributes more than 25 years of research, drug development, and executive 

management experience to the Leukemia and Lymphoma Society. He has held academic 

appointments at Max Planck Institute in Munich, Germany, and the University of Massachusetts 

Medical School. DeGennaro’s private-sector positions include senior director of molecular 

genetics at Wyeth Pharmaceuticals and executive vice president for research and development 

at SynX Pharma, Inc. He received his doctorate in biochemistry from the University of California, 

San Francisco and did his postdoctoral research at Yale University School of Medicine. 

JOsePh degeORge 

Global Head of Safety Assessment, Merck Research Laboratories 

Joseph DeGeorge was hired by Merck in 2004 as vice president of global safety assessment. 

Since then, he has been named global head of safety assessment and laboratory animal 

resources. At Merck, he has served on or chaired committees on drug discovery, drug candidate 

selection, early and late stage development, and post marketing safety. Before working at 

Merck, he served as vice president of preclinical safety evaluation at Novartis Pharmaceuticals 

and as the global chair for the Research and Development Safety Assessment Committee. 

Prior to Novartis, he worked at FDA, where he was the associate director for pharmacology and 

toxicology at CDER. Prior to joining FDA, DeGeorge was a senior staff fellow at the National 

Institute on Aging’s Laboratory of Neurosciences. DeGeorge received his PhD in Pharmacology 

from the State University of New York/Upstate Medical Center. 

panelists 47

48 

susan denTzeR 

Editor-in-Chief, Health Affairs 

Susan Dentzer is the editor-in-chief of Health Affairs, the nation’s leading journal on health 

policy, and is an on-air analyst on health issues with PBS NewsHour. She previously led 

NewsHour’s health unit, reporting extensively on-air about healthcare reform debates. 

She is an elected member of the Institute of Medicine and the Council on Foreign Relations. 

Dentzer completed her undergraduate degree at Dartmouth College and is a trustee emerita 

of the school. She currently serves as a member of the Board of overseers of Dartmouth 

Medical School. She is also on the board of directors of Research!America. 

JOsePh desiMOne 

Director, Frank Hawkins Kenan Institute of Private Enterprise, and Professor of Chemistry, 

University of North Carolina 

Joseph DeSimone is a professor of chemical engineering at North Carolina State University and 

professor of chemistry at the University of North Carolina (UNC) at Chapel Hill. He is also the 

director of the Frank Hawkins Kenan Institute of Private Enterprise at UNC. His research group is 

currently focused on harnessing the fabrication technologies from the semiconductor industry 

to design high-performance, cost-effective vaccines and medicines. Additionally, he is an 

adjunct member at Memorial Sloan-Kettering Cancer Center. DeSimone is a member of 

both the National Academy of Sciences and the National Academy of Engineering. In 2004, 

he launched Liquidia Technologies, which has raised more than $60 million in venture 

financing, including the first-ever equity investment by the Bill and Melinda Gates Foundation 

in a for-profit biotech company. DeSimone has more than 130 issued patents in his name, 

with more than 80 patents pending. He received his bachelor of science in chemistry from 

Ursinus College and his doctorate in chemistry from Virginia Tech.

MikaeL dOLsTen 

President, Worldwide Research and Development, Pfizer 

Mikael Dolsten is the president of worldwide research and development at Pfizer, advancing 

its leadership in small molecule science and medicines, as well as its leadership, expertise, 

and innovation in the areas of biotherapeutics and vaccines. Dolsten is also co-chair of the 

company’s Portfolio Strategy and Investment Committee, which governs major pipeline 

investments and strategic R&D priorities. Previously, Dolsten was president of BioTherapeutics 

R&D, responsible for driving Pfizer leadership, expertise, and innovation in biologic medicines 

and vaccines. Prior to joining Pfizer in 2009, Dolsten was senior vice president at Wyeth Inc. 

Before joining Wyeth, he served as executive vice president within Pharmaceutical Research 

& Development/Medicine at Boehringer Ingelheim. Dolsten earned his doctorate in tumor 

immunology and medical degree from the University of Lund in Sweden. 

FRank L. dOugLas 

President and CEO, Austen BioInnovation Institute 

Frank Douglas is the president and CEO of Austen BioInnovation Institute, which is a unique 

model for the future of healthcare delivery and innovation. Additionally, he is a professor in 

the College of Polymer Science and Engineering at The University of Akron. Previously, 

Douglas served as senior partner at Puretech Ventures, executive vice-president and chief 

scientific officer of Aventis, and chief scientific adviser for Bayer Healthcare, AG. He also 

founded and directed the Massachusetts Institute of Technology’s Center of Biomedical 

Innovation. He received his doctorate in physical chemistry and his medical degree from 

Cornell University. He completed his internship and residency in internal medicine at The 

Johns Hopkins Medical Institutions and a fellowship in neuroendocrinology at the National 

Institutes of Health. 

panelists 49

50 

Jens eCksTein 

President, SR One 

Jens Eckstein was named president of SR One, GlaxoSmithKline’s independent healthcare 

venture capital organization, in October 2011. Previously, Eckstein worked for TVM Capital 

in the role of general partner in the firm’s life sciences practice and focused on early-stage 

investments. He then moved up to be venture partner and entrepreneur-in-residence at TVM 

and was appointed interim CEO and president of SelectX Pharmaceuticals. Prior to joining TVM 

Capital, Eckstein led drug discovery programs at Enanta Pharmaceuticals, Inc. and Mitotix, Inc. 

He is the author of more than 25 scientific publications and holds several issued and pending 

patents. Eckstein is an advisor to the Alzheimer Research Forum, founding member of the Cure 

Dystonia Initiative Advisory Council, and a Kauffman Fellow. 

daLe edgaR 

Lilly Distinguished Research Fellow, Global Head, Science and Technology Partnerships, LRL 

Dale Edgar is responsible for consortia and public private partnerships across the Lilly 

research enterprise. His executive responsibilities include strategy and governance of research 

partnerships and oversight of Lilly’s global Post-Doctoral Scientist Training Program. 

Edgar previously served as chief scientist and global head of Lilly’s Discovery Sleep Research 

program. Prior to joining Lilly, Edgar was co-founder, vice president, and the chief science 

& technology officer of Hypnion Inc., which Lilly acquired in April 2007. Edgar was also an 

associate professor of psychiatry & behavioral sciences and director of the Sleep and Circadian 

Neurobiology Laboratory at the Stanford University School of Medicine. Edgar has numerous 

publications and issued patents, and a successful track record of delivering compounds from 

inception to the clinic. He received his master’s degree from San Jose State University and his 

doctorate from the University of California.

JOn FRedRiCksOn 

Vice President, Government Practice, Innocentive 

Jon Fredrickson focuses on InnoCentive’s efforts with the public sector and government. 

He leads a team of professionals whose mission is to help governments identify and 

implement new strategies and solutions for using Open Innovation and InnoCentive’s 

exclusive methodology of Challenge Driven Innovation to optimize public spending and 

accelerate innovation into the government initiatives and programs. Prior to Innocentive, 

he led teams in building new businesses and best practices within Fortune 100 companies 

and federal, state, and local governments. Fredrickson is a frequent speaker at global 

innovation forums. He received his bachelor’s degree from Bethel University. 

MaRia FReiRe 

President, Foundation for the NIH 

Maria Freire is the president of the Foundation for the NIH, where she began her tenure 

in November 2012. Prior to this, she served as president of the Albert and Mary Lasker 

Foundation. She has also fulfilled the roles of president and CEO of the Global Alliance for 

TB Drug Development, director of the Office of Technology Transfer at the National Institutes 

of Health, and director of the University of Maryland at Baltimore’s Office of Technology 

Development. Freire received her bachelor of science from the Universidad Peruana Cayetano 

Heredia in Lima, Peru, and her doctorate in biophysics from the University of Virginia. 

panelists 51

52 

sTePhen FRiend 

President, Sage Bionetworks 

Stephen Friend is president of Sage Bionetworks, a nonprofit biomedical research organization 

that aims to create a revolutionary open access approach to human biological information 

and the treatment of disease. Previously senior vice president and franchise head for oncology 

research at Merck & Co., Friend led Merck’s basic cancer research efforts. Prior to that, he joined 

the Fred Hutchinson Cancer Research Center’s Seattle Project, an advanced institute for drug 

discovery. He has also held faculty positions at Harvard Medical School and Massachusetts 

General Hospital. He received a bachelor of arts in philosophy, a doctorate biochemistry, 

and a medical degree from Indiana University. 

kaThy giusTi 

Founder and CEO, Multiple Myeloma Research Foundation 

Kathy Giusti is the founder and CEO of the Multiple Myeloma Research Foundation (MMRF) 

and the Multiple Myeloma Research Consortium (MMRC). Shortly after being diagnosed 

with multiple myeloma, an incurable blood cancer, she founded the MMRF in 1998 to fund 

innovative myeloma research and drug discovery. She then founded the MMRC in 2004 

to enable leading research institutions to work with industry to speed the discovery and 

development of effective new treatments for myeloma. Giusti has served on the Institute of 

Medicine’s National Cancer Policy Board and the Cancer Leadership Council. She currently 

serves on the National Cancer Advisory Board, the Board of Directors for IMS Health, and is a 

member of the Health Research Alliance. Giusti graduated from Harvard Business School with 

a master of business administration in general management and 

began her career with Merck & Co.

sCOTT gOTTLieB 

Resident Fellow, American Enterprise Institute 

Scott Gottlieb is a practicing physician and resident fellow at the American Enterprise 

Institute. His research interests include trends in medicine, medical technology development, 

FDA policies, and Center for Medicare and Medicaid Services policies. Gottlieb has held a 

distinguished career with the FDA, serving in several capacities including senior adviser for 

medical technology, director of medical policy development, and deputy commissioner for 

medical and scientific affairs. He also sits on the board of several institutions, including the 

Leukemia and Lymphoma Society, Cancer Commons, and Society for Hospitalist Medicine. 

He is also a clinical assistant professor at the NYU School of Medicine. He holds a medical 

degree from Mount Sinai School of Medicine and a bachelor of arts in economics from 

Wesleyan University. 

dan haRTMan 

Director, Integrated Development, Bill and Melinda Gates Foundation 

Dan Hartman is the director, Integrated Development, at the Bill and Melinda Gates Foundation. 

He joined the foundation in 2012 and leads a team that provides expertise in drug and 

diagnostic development. His team works closely with the foundation’s strategy teams to 

manage product pipelines through clinical trials as well as provide help with manufacturing, 

compliance, and regulatory strategy. Hartman joined the foundation after four years as 

president and CEO of Great Lakes Development Inc., a consulting company providing 

strategic and operational support for early drug development projects. Previously, 

Hartman served as senior vice president of product development at deCODE genetics, 

executive director of Pfizer Global Research and Development, vice president of global 

clinical development at Esperion Therapeutics, and senior clinical research positions at 

Eli Lilly & Company. Hartman received his bachelor’s degree from Calvin College and his 

medical degree from Wayne State University. 

panelists 53

54 

MaTTheW heRPeR 

Senior Editor, Forbes Magazine 

Matthew Herper is currently a senior editor at Forbes Magazine. He has covered science and 

medicine from the Human Genome Project through Vioxx to the blossoming DNA technology 

changing the world today. He consistently covers the biotechnology and pharmaceutical 

industry and is one of the most prominent journalists in this space. Herper received his 

bachelor of science from the Massachusetts Institute of Technology and his master of science 

in journalism from Columbia University. 

CLiFFORd a. hudis 

Chief, Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center; President-elect, 

American Society of Clinical Oncology 

Clifford A. Hudis is chief of the Breast Cancer Medicine Service and an attending physician at 

Memorial Sloan-Kettering Cancer Center. He is also professor in the Department of Medicine 

at Weill Cornell Medical College. Hudis will assume his role as American Society of Clinical 

Oncology president in June 2013. His research interests include all areas of care related to 

breast cancer, with a focus on the development of novel systemic therapies. Hudis completed 

his undergraduate studies at Lehigh University and pursued his medical degree, internship, 

and residency at the Medical College of Pennsylvania.

RiChaRd a. inseL 

Chief Scientific Officer, JDRF 

Richard Insel is the chief scientific officer for JDRF. In this role, which he has held since 2003, 

he is responsible for the strategic direction and oversight of all JDRF research projects. Prior to 

assuming this position, Insel held various leadership positions at the University of Rochester 

Medical Center, including acting chair of pediatrics and associate chair for pediatric research. 

He was also a co-founder of Praxis Biologics, a biotechnology company acquired by Wyeth that 

brought a vaccine to market that led to the virtual elimination of the most common form of 

childhood meningitis among American children. 

ThOMas R. inseL 

Director, National Institute of Mental Health, National Institutes of Health 

Thomas Insel is the director of the National Institute of Mental Health (NIMH) at the National 

Institutes of Health (NIH). Earlier in 2012, he served as acting director of the National Center 

for Advancing Translational Sciences. Prior to this, Insel was a professor of psychiatry at Emory 

University; founding director of the Center for Behavioral Neuroscience, one of the largest 

National Science Foundation-funded science and technology centers; director of an NIHfunded 

Center for Autism Research; and director of the Yerkes Regional Primate Center in 

Atlanta. A focus of his work has involved examining the role of the neuropeptides oxytocin 

and vasopressin in social attachment and in aggressive behavior. He also conducted clinical 

research on obsessive-compulsive disorder. Insel received his bachelor of arts and medical 

degrees from Boston University. 

panelists 55

56 

eLizaBeTh iORns 

Co-Founder and CEO, Science Exchange 

Elizabeth Iorns is an assistant professor in the Department of Medicine at the University of 

Miami and the co-founder & CEO of Science Exchange, an online marketplace for science 

experiments. She co-founded Science Exchange in 2011 based on her own difficulties 

accessing core facility capabilities and collaborations outside her home university. To solve 

this issue, Science Exchange allows scientists to search a central database of scientific services 

offered by more than 1,000 core facilities and commercial providers. Iorns’ specialty is breast 

cancer research. She received her doctorate in cancer biology from the Institute of Cancer 

Research in London. 

CheRyL JaegeR 

Senior Policy Advisor, Majority House Leadership, U.S. House of Representatives 

Cheryl Jaeger is the senior health policy advisor to the Majority Leader of the U.S. House of 

Representatives, Eric Cantor. In this role, she leads the advancement of healthcare reform 

legislation to improve patient choice, lower healthcare costs, and expand innovation. Jaeger 

previously served as a senior advisor to the former Majority Whip Roy Blunt. Prior to serving as 

a leadership aide, Jaeger worked as a professional staff member for the Committee on Energy 

and Commerce. She was the lead staff negotiator of the NIH Reform Act of 2006 in addition to 

several other pieces of legislation. Jaeger began her tenure on Capitol Hill nearly 14 years ago 

as a legislative aide to former Congressman Christopher Cox. Jaeger earned a master in public 

policy from Georgetown University and is a graduate of the University of Virginia.

gauTaM Jaggi 

Global Lead Analyst/Editor of Beyond Borders and Progressions, 

Ernst & Young Global Life Sciences Center 

Gautam Jaggi leads the development of Ernst & Young’s (EY) life sciences thought leadership. 

He is the lead author and managing editor of two of the firm’s foremost publications: 

Progressions (EY’s annual pharmaceutical industry report) and Beyond Borders (EY’s annual 

biotechnology industry report). Jaggi is also lead analyst for life sciences with Ernst & Young’s 

Knowledge group. He writes and speaks extensively on business and strategic challenges facing 

the life sciences industry. Prior to his current role, Jaggi provided economic consulting services 

to life sciences clients and conducted economic research at a leading think tank. 

sCOTT JOhnsOn 

President, CEO, and Founder, Myelin Repair Foundation 

Scott Johnson is the president, CEO, and founder of the Myelin Repair Foundation. He brings 

more than 20 years of experience in business to his role. Johnson led several start-ups in 

industries ranging from biotechnology to food to entertainment. Before these entrepreneurial 

roles, Johnson was an executive at FMC Corporation and in management consulting at the 

Boston Consulting Group. He holds a master of business administration from the University of 

California, Berkeley Haas School of Business and a bachelor of science in civil engineering from 

the University of California, Davis. Johnson was diagnosed with multiple sclerosis in 1976. 

panelists 57

58 

sTePhen JOhnsOn 

Partner, Kirkland & Ellis LLP 

Stephen Johnson is the senior partner in Kirkland’s San Francisco intellectual property group. 

He is also a founding partner of both Kirkland’s San Francisco and New York offices and the 

former head of Kirkland’s New York intellectual property group. Johnson usually works on 

cases where a client is entering into critical transactions with third parties such as outsourcing 

major functions or where a new transaction structure may be required. He also works on 

novel IP transactions. Johnson formerly served as senior chair of Technology Committee of the 

International Bar Association. Johnson’s experience has been widely recognized; in 2010, 

he was named to Intellectual Asset Management magazine’s list of the world’s top 250 patent 

and technology licensing lawyers. 

Regis B. keLLy 

Director, The California Institute for Quantitative Biosciences (QB3), University of California 

Regis B. Kelly is director of the California Institute for Quantitative Biosciences, an innovation 

center made up of more than 200 quantitative biologists at three northern California campuses 

working at the interface of the physical and biological sciences. It is one of four California 

Institutes for Science and Innovation created by the California legislature to strengthen the 

academic foundation of its technology-based industries. From 2000 to 2004, Kelly served as 

executive vice chancellor at the University of California, San Francisco, and, before that, was 

chair of the department of biochemistry and biophysics. He is also a general partner of Mission 

Bay Capital venture fund. Kelly received his bachelor’s degree in physics from the University of 

Edinburgh in Scotland and his doctorate in biophysics from the California Institute of Technology.

JOnaThan LeFF 

Managing Director, Warburg Pincus 

Jonathan Leff is a managing director with Warburg Pincus, where he has been a member 

of the HealthCare Group since 1996. Leff is responsible for the firm’s investment efforts 

in biotechnology. Currently he is a director of Allos Therapeutics, InterMune, ReSearch 

Pharmaceutical Services, Sophiris Bio, Rib-X Pharmaceuticals, and Talon Therapeutics. 

In addition, he serves on the Executive Committee of the board of the National Venture 

Capital Association and leads its life sciences industry efforts as chairman of its Medical 

Innovation and Competitiveness Coalition. Leff is a board member of the Biotechnology 

Industry Organization as well as Friends of Cancer Research and the Spinal Muscular 

Atrophy Foundation. He also sits on the Board of Visitors of Columbia University Medical 

Center. Leff received a bachelor of arts from Harvard University and a master of business 

administration from Stanford University. 

LaWRenCe J. LeskO 

Professor of Pharmaceutics, Director, Center for Pharmacometrics and Systems Pharmacology, 

University of Florida 

Lawrence Lesko has been leading The University of Florida’s Center for Pharmacometrics and 

Systems Pharmacology since July 2011. Before assuming this position, Lesko worked for nearly 

20 years as the director of the Office of Clinical Pharmacology for the Center for Drug Evaluation 

and Research at FDA. Lesko’s research interests include drug development and regulatory 

science, quantitative clinical pharmacology, and pharmacogenomics. Lesko received both a 

bachelor of science and doctorate from Temple University Health Science Center. 

panelists 59

60 

shaRi Ling 

Deputy Chief Medical Officer, Centers for Medicare & Medicaid Services 

Shari Ling is currently the Centers for Medicare and Medicaid Services (CMS) deputy chief 

medical officer. Ling has a special interest in the care of persons with multiple chronic 

conditions and functional limitations and reducing health disparities. Ling represents CMS on 

various Health and Human Services (HHS) workgroups, including the HHS National Alzheimer’s 

Project Act. After completing her medical degree, Ling served on the faculty of Johns Hopkins 

University School of Medicine and continues to teach there and at the University of Maryland. 

Ling is a geriatrician and rheumatologist who received her medical training at Georgetown 

University School of Medicine. 

anMOL Madan 

Co-founder, CEO, and Data Scientist, Ginger.io 

Anmol Maden leads the overall product vision at Ginger.io and has extensive research 

experience in modeling large-scale human behavior data using statistical and pattern 

recognition methods. His past research has been featured in academic publications in 

computer science. He previously worked on Windows Mobile with Microsoft. He received 

his doctorate from the Media Lab at the Massachusetts Institute of Technology.

PeTeR MaRgOLis 

Professor of Pediatrics and Director of Research, James M. Anderson Center for Health 

Systems Excellence, Cincinnati Children’s Hospital Medical Center, University of Cincinnati 

School of Medicine 

Peter Margolis is professor of pediatrics and director of research at the James M. Anderson 

Center for Health Systems Excellence at Cincinnati Children’s Hospital Medical Center. He has 

been with the center since 2006. Margolis also works extensively with the certifying boards 

and specialty societies to assist in designing programs that will enable physicians to meet new 

Maintenance of Certification requirements on systems thinking and performance practices. 

He was a Robert Wood Johnson Generalist Faculty Scholar at the University of North Carolina, 

where he also served on the faculty between 1991 and 2005. Margolis holds a medical degree 

from New York University and did his pediatric training at the University of Colorado. 

MiChaeL MiLken 

Chairman, Milken Institute; Founder, FasterCures 

Mike Milken has been at the forefront of a wide range of initiatives that have influenced public 

policy, accelerated medical research, and expanded access to capital. Fortune magazine 

called him “The Man Who Changed Medicine” for “shaking up the medical establishment and 

saving lives.” He is chairman of the Milken Institute and FasterCures, founder of the Melanoma 

Research Alliance, and the inspiration behind several philanthropic initiatives worldwide. 

In 1982, Mike co-founded the Milken Family Foundation, which supports education reform 

and research on a wide range of life-threatening diseases. As a financier, he is often said to 

have revolutionized modern capital markets by expanding access to capital for more than 

3,200 growing companies that created millions of jobs. He graduated with highest distinction 

from UC Berkeley and earned his M.B.A. at the Wharton School. Mike and his wife of 44 years, 

Lori, have three children and seven grandchildren. More details are at www.mikemilken.com. 

panelists 61

62 

BeRnaRd MunOs 

Chief Apostle, Breakthrough Innovation, InnoThink 

Bernard Munos is the founder of InnoThink, a consultancy that focuses on pharmaceutical 

innovation - specifically, where it comes from and how to get more of it. He was previously an 

advisor for corporate strategy at Eli Lilly, where he focused on disruptive innovation and the 

radical redesign of R&D. His research has been published in Nature and Science, and he was 

recently profiled by Forbes magazine. This year, the popular industry newsletter FiercePharma 

named him one of the 25 most influential people in biopharma today. Munos received a 

master of business administration from Stanford University, and holds graduate degrees in 

agricultural economics and animal science from the University of California, Davis, and the 

Paris Institute of Technology for Life, Food and Environmental Sciences. 

gaRRy neiL 

Partner, Apple Tree Partners 

Garry Neil is a partner at Apple Tree Partners and head of R&D at Apple Tree Pharmaceuticals. 

He has had broad experience in science, medicine, and pharmaceutical development. 

Neil previously held a number of senior positions within Johnson & Johnson, including the 

corporate vice president in the Office of Science and Technology. He was also group president 

of Johnson & Johnson Pharmaceutical Research and Development. Under his leadership, 

a number of important new medicines for the treatment of cancer, anemia, infections, 

central nervous system and psychiatric disorders, pain, and genitourinary and gastrointestinal 

diseases gained initial, new, or expanded indication approvals. Neil holds a medical degree 

from the University of Saskatchewan’s College of Medicine.

saLLy Okun 

Health Data Integrity Manager, PatientsLikeMe 

Sally Okun is the head of health data integrity and patient safety at PatientsLikeMe. In this role, 

she is a member of the Research, Data and Analytics Team. Prior to joining PatientsLikeMe, 

Okun, a registered nurse, specialized in palliative and end of life care and contributed to 

clinical, research, and education projects of national significance. She is a member of the 

Institute of Medicine’s Clinical Effectiveness Research Innovation, Evidence Communication 

Innovation, and Best Practices Innovation collaboratives. Okun received a master’s degree 

from The Heller School at Brandeis University; studied palliative care and ethics at Memorial 

Sloan-Kettering Cancer Center; and completed the National Library of Medicine Biomedical 

Informatics Fellowship program. 

dOMinique Pahud 

Director, Advancing Innovation, Ewing Marion Kauffman Foundation 

Dominique Pahud is a director in advancing innovation at the Ewing Marion Kauffman 

Foundation. Prior to joining the foundation, he held several positions in R&D and commercial 

at Genentech, Inc. in San Francisco, most recently serving as international payer strategy 

leader in oncology, where he led the global development and implementation of strategies to 

assure patient access to the next generation of novel cancer therapies. While at Genentech, 

he received several awards for his extraordinary work and customer focus. Earlier, Pahud worked 

in business development at Celgene Corporation in Warren, NJ, and at LedbetterStevens in 

New York, where he led searches for the recruitment of senior executives in the life science 

industry. Pahud earned a master of business administration in finance from Columbia 

Business School in New York and a bachelor of science in cellular molecular biology from 

the University of Michigan. 

panelists 63

64 

sTeLiOs PaPadOPOuLOs 

Co-Founder and Chairman, Exelixis 

Stelios Papadopoulos co-founded Exelixis and has been the director since 1994 and 

the chairman since 1998. He has an extensive investment banking and biotechnology 

background, including time spent at Cowen & Co.; Drexel Burnham Lambert; Donaldson, 

Lufkin & Jenrette; and Anadys Pharmaceuticals, Inc. Before coming to Wall Street in 1985, 

Papadopoulos was on the faculty of the department of cell biology at New York University 

Medical Center. He continues his affiliation with New York University Medical Center as an 

adjunct associate professor of cell biology. Papadopoulos has served as a member of the 

board of BG Medicine, Biogen Idec, GenVec, SGX Pharmaceuticals, Cellzome, Joule Unlimited, 

and Regulus Therapeutics. Papadopoulos is also a co-founder and chairman of Fondation 

Sante and a member of the board of visitors of Duke University Medical Center. Papadopoulos 

holds a doctorate in biophysics and a master of business administration in finance, both from 

New York University. 

david PaRkinsOn 

Venture Partner, New Enterprise Associates 

David Parkinson is a venture partner at New Enterprise Associates. From 2007 to 2012, 

Parkinson served as president and CEO of Nodality, a biotechnology company that develops 

technologies to enable personalized medicine and more efficient drug development in cancer 

and autoimmune diseases. Before joining Nodality, Parkinson was a senior vice president at 

Biogen Idec. He has also served tenures in a vice presidential role at Amgen and Novartis. Prior 

to joining Novartis, Parkinson served at the National Cancer Institute. He had previously held 

positions at the M.D. Anderson Cancer Center, University of Texas, and New England Medical 

Center. He received his medical degree from the University of Toronto, with some training at 

McGill University and New England Medical Center.

sTeven MaRC PauL 

Director, Helen & Robert Appel Institute for Alzheimer’s Research, Weill Cornell Medical College 

Steven M. Paul is the director of the Helen and Robert Appel Alzheimer’s Disease Research 

Institute and a professor of neuroscience, psychiatry, and pharmacology at Weill Cornell 

Medical College. He was formerly the president and executive vice president of science and 

technology of the Lilly Research Laboratories of Eli Lilly and Company. In 2005, Paul was 

named Chief Scientific Officer of the Year as one of the Annual Pharmaceutical Achievement 

Awards. Prior to assuming his position at the Lilly Research Laboratories, Paul also served as 

medical director in the Commissioned Corps of the United States Public Health Service. Paul 

received his bachelor of arts in biology and psychology, his master of science in anatomy, 

and his medical degree from Tulane University. 

MiChaeL PeLLini 

President and CEO, Foundation Medicine 

Michael Pellini joined Foundation Medicine as president and CEO in 2011. He came to 

Foundation Medicine from Clarient, a GE Healthcare Company, where he held the position of 

president and chief operating officer. In this capacity, he worked to drive critical regulatory 

and reimbursement strategies in parallel with the development and commercialization of 

multiple diagnostic tests. Prior to his tenure with Clarient, Pellini served at several life sciences 

companies, including Safeguard Scientifics, Inc., Lakewood Pathology Associates, BioAdvance, 

and Genomics Collaborative, Inc. Pellini received a bachelor of arts from Boston College, 

a master of business administration from Drexel University, and a medical degree from 

Jefferson Medical College of Thomas Jefferson University. 

panelists 65

66 

eRiC d. PeRaksLis 

Chief Information Officer and Chief Scientist (Informatics), U.S. Food and Drug Administration 

Eric Perakslis is the chief information officer and chief scientist (informatics) at the U.S. Food 

and Drug Administration (FDA). He is responsible for modernizing and enhancing the IT 

capabilities and scientific capabilities at FDA. Previously, Perakslis spent 13 years at Johnson & 

Johnson, culminating in the position of senior vice president of R&D information technology. 

He is also a late-stage kidney cancer survivor and an avid patient advocate. Perakslis has a 

doctorate in chemical and biochemical engineering from Drexel University. 

kiM J. POPOviTs 

President and CEO, Genomic Health, Inc. 

Kim Popovits has served as president and CEO of Genomic Health since 2009 and as president 

and chief operating officer since 2002. Prior to joining Genomic Health, Popovits served in 

various roles, most recently as senior vice president of marketing and sales, at Genentech, 

Inc. During her 15 years at Genentech, she led the successful commercialization of 14 new 

therapies, including Herceptin. Before joining Genentech, Popovits served as division manager 

for American Critical Care. In 2008, Popovits was named Woman of the Year by the Women 

Health Care Executives, and she has been named one of the Most Influential Women in the Bay 

Area by The San Francisco Business Times from 2006 to 2011. She holds a bachelor of arts in 

business from Michigan State University.

WendeLL PRiMus 

Senior Health Policy Advisor, Minority House Leadership, U.S. House of Representatives 

Wendell Primus is the senior policy advisor on health issues to Leader Nancy Pelosi. Prior to 

this appointment, Primus was the minority staff director at the Joint Economic Committee. 

Prior to that position, Primus was the director of income security for the Center on Budget and 

Policy Priorities. He also previously served in the Clinton Administration as a deputy assistant, 

as the secretary for human services policy at the Department of Health and Human Services. 

Primus has also served as chief economist for the House Ways and Means Committee and 

staff director for the Committee’s Subcommittee on Human Resources. Primus received his 

doctorate in economics from Iowa State University. 

TeResa sTanek Rea 

Deputy Director, U.S. Patent and Trademark Office 

Teresa Rea joined the U.S. Patent and Trademark Office (USPTO) in 2011 as deputy director. 

She has more than 25 years of legal experience in the field of intellectual property and is a 

former president of the American Intellectual Property Law Association. Before joining the 

USPTO, Rea was a partner in Crowell & Moring LLP’s Washington office, where she focused 

on intellectual property and dispute resolution related to pharmaceutical, biotechnology, 

and other life science issues. Rea received her law degree from Wayne State University and her 

bachelor of science in pharmacy from the University of Michigan. 

panelists 67

68 

ROBeRT Ring 

Vice President, Translational Research, Autism Speaks 

Robert Ring was named vice president of translational research at Autism Speaks in May 2011. 

In this capacity, he focuses on moving Autism Speaks’ biological sciences program from the 

laboratory into the clinic. Prior to this, Ring served as senior director and head of the Autism 

Research Unit at Pfizer, the first research and development unit in the pharmaceutical industry 

entirely focused on developing medications for autism spectrum disorders. He also spent time 

at Wyeth Pharmaceuticals in its neuroscience division. Ring earned his doctorate in molecular 

neurobiology at the City of Hope National Medical Center. 

TOMasz saBLinski 

Founder, Transparency Life Sciences; Head of Development, Celtic Therapeutics 

Tomasz Sablinski is currently the founder of Transparency Life Sciences (TLS) as well as 

the head of development and a managing director of Celtic Therapeutics Development. 

He founded TLS in 2010, stimulated by the opportunities to introduce a new model of drug 

development afforded by modern computer sciences, technology, and new communication 

patterns. Previously, he served as vice president of Novartis Pharmaceutical Corp., where he 

was in charge of U.S. clinical development and medical affairs. Prior to this, Sablinski was a 

consultant to several biotechnology companies. Overall, Sablinski has more than 30 years 

of experience in healthcare. He received his medical degree and doctorate from the Academy 

of Medicine in Warsaw.

Jay sChniTzeR 

Director, Defense Sciences Office, Defense Advanced Research Projects Agency (DARPA) 

Jay Schnitzer is the director of the Defense Sciences Office (DSO) at the Defense Advanced 

Research Projects Agency. He joined DSO in September 2011, and his research focuses on 

the interface between healthcare simulation and medical disaster preparedness. Previously 

Schnitzer was an associate chief medical officer and vice president at Boston Scientific 

Corporation. Prior to that, he was an associate professor of surgery at Harvard Medical School 

and a surgeon at Massachusetts General Hospital, Shriners Burn Hospital, and Children’s 

National Medical Center. He also spent a year performing trauma surgery in the Gaza Strip. 

Schnitzer has a bachelor’s degree in chemical engineering from Worcester Polytechnic Institute, 

a doctorate in chemical engineering from the Massachusetts Institute of Technology, and a 

medical degree from Harvard Medical School. 

Wendy seLig 

President and CEO, Melanoma Research Alliance 

Wendy K.D. Selig is president and CEO of the Melanoma Research Alliance (MRA), a public 

charity focused on finding and funding the most promising melanoma research worldwide 

that will accelerate progress toward a cure. Founded by Debra and Leon Black in 2007 and 

established under the auspices of the Milken Institute, MRA has provided more than 

$30 million for cutting-edge research in the areas of melanoma prevention, diagnosis, and 

treatment. Previously, Selig spent nearly a decade in leadership positions at the American 

Cancer Society (ACS) and the ACS Cancer Action Network. Selig earned her bachelor’s degree 

from Princeton University and master’s degree from Northwestern University’s Medill School 

of Journalism. 

panelists 69

70 

viCki seyFeRT-MaRgOLis 

Senior Advisor, Science Innovation and Policy, Office of the Commissioner, 

U.S. Food and Drug Administration 

Vicki Seyfert-Margolis is senior advisor for science innovation and policy in the FDA 

Commissioner’s Office, focusing on innovation, regulatory science, personalized medicine, 

scientific computing, and health informatics. Previously, she was chief scientific officer at the 

Immune Tolerance Network (ITN), a research consortium seeking treatments for immune 

system diseases. At ITN, she oversaw the development of 20 laboratory facilities and the 

design and execution of biomarker discovery studies for more than 25 Phase II clinical trials. 

In her biomarker efforts, she established construction of a primer library of 1,000 genes that 

may be involved in immunologic tolerance and co-discovered genes that may mark kidney 

transplant tolerance. Seyfert-Margolis was also an adjunct associate professor at the 

University of California, San Francisco. Prior to academia, she directed the Office of Innovative 

Scientific Research Technologies at the National Institute of Allergy and Infectious Diseases. 

Seyfert-Margolis earned a doctorate in immunology at the University of Pennsylvania’s 

school of medicine. 

Ben shaPiRO 

Senior Partner and Chair, PureTech Ventures 

Bennett Shapiro is senior partner and chair of PureTech Ventures. From 1990-2003 he was 

executive vice president of Merck Research Laboratories where he initially led all basic and 

preclinical research activities worldwide and then all of Merck’s external research. Prior to 

Merck, Shapiro was a professor and chairman of the Department of Biochemistry at the 

University of Washington. He has a BS in Chemistry from Dickinson and MD from Jefferson 

Medical College. He is currently Chair of VBL Therapeutics, a Board Director of Momenta 

Pharmaceuticals and the Drugs for Neglected Diseases initiative, and a co-founder of Satori, 

Vedanta Biosciences, Gelesis, and Akili.

TOdd sheReR 

CEO, The Michael J. Fox Foundation for Parkinson’s Research 

Todd Sherer is the CEO of The Michael J. Fox Foundation for Parkinson’s Research. Sherer’s 

work with the foundation began in 2003, when he received a grant to investigate the role 

of environmental factors in causing Parkinson’s. Since 2006, Sherer has led the foundation’s 

efforts to define high-priority research areas and to strategically allocate funding to move 

projects closer to the clinic. He also has played major roles in the foundation’s strategies to 

increase the pharmaceutical industry’s investment in Parkinson’s disease drug development 

and engage the patient community. He holds a doctorate in neuroscience from the University 

of Virginia and a bachelor’s degree in psychology from Duke University. 

gReg siMOn 

CEO, Poliwogg 

Greg Simon is the CEO of Poliwogg, an online crowd-financing marketplace that matches 

young companies with sophisticated investors. Poliwogg concentrates in healthcare, yieldbased 

investments, and community enterprises. Previously, Simon was the founding president 

of FasterCures, held senior positions in both chambers of Congress and the White House, was a 

senior strategy consultant to a variety of international technology CEOs, and served as senior 

vice president at Pfizer for World Wide Policy and Patient Engagement. 

panelists 71

72 

JOnaThan siMOns 

President and CEO, Prostate Cancer Foundation 

Jonathan Simons is the president, CEO, and David H. Koch Chair of the Prostate Cancer 

Foundation, a position he has held since 2007. An internationally recognized prostate cancer 

oncologist, physician-scientist, and biomedical inventor, he also served as interim chief science 

officer of the Melanoma Research Alliance during its launch by FasterCures in 2008. In 2000, 

Simons was recruited from the Johns Hopkins Cancer Center by Georgia Gov. Roy Barnes 

and the Woodruff Foundation of Atlanta to be the founding director of the Winship Cancer 

Institute at Emory University. Simons launched the first National Cancer Institute Cancer 

Nanotechnology Centers at Emory and Georgia Tech in 2004. He is a graduate of Princeton 

University and the Johns Hopkins University School of Medicine and did postgraduate 

fellowships at Cambridge University and Harvard Medical School. 

susan sOLOMOn 

CEO and Co-Founder, New York Stem Cell Foundation 

Susan L. Solomon is a co-founder and the CEO of the New York Stem Cell Foundation. 

She is also the chair and a founding member of New Yorkers for the Advancement of Medical 

Research and has served on the board of the Juvenile Diabetes Research Foundation in New 

York. An attorney, Solomon practiced law with Debevoise & Plimpton before beginning a 

25-year career in new media, entertainment, and investment banking. During this time, 

she served as the founding CEO of Sothebys.com and as president and CEO of Sony Worldwide 

Networks. She received a bachelor of arts from New York University and a law degree from 

Rutgers University School of Law.

gaRen sTagLin 

Co-founder, One Mind for Research 

Garen Staglin is an accomplished businessman who co-founded, along with Congressman 

Patrick Kennedy, One Mind For Research. Staglin was touched by mental illness several years 

ago when his son was diagnosed with schizophrenia. Since then, Staglin has worked to battle 

mental illness through philanthropic efforts that include founding the International Mental 

Health Research Organization, BringChange2Mind.org, and One Mind for Research. Outside of 

his philanthropic efforts, Staglin served as a lieutenant in the U.S. Navy, has extensive venture 

capital experience, and owns a vineyard in Napa Valley. Staglin completed his undergraduate 

degree at University of California, Los Angeles and his master of business administration at 

Stanford University. 

MeLissa sTevens 

Deputy Executive Director, FasterCures 

Melissa Stevens is deputy executive director of FasterCures / The Center for Accelerating 

Medical Solutions. She manages the planning and implementation of the organization’s 

programs and priorities. She also directs the organization’s medical philanthropy efforts 

including the Philanthropy Advisory Service, designed to help foundations, philanthropists, 

and their advisors make more impactful investments in medical research and better 

assess the return on philanthropy. Previously, she worked in the health sciences practice 

of PricewaterhouseCoopers, advising commercial and federal clients across the healthcare 

continuum. Stevens received both her bachelor’s degree in biochemistry and master of 

business administration from Pennsylvania State University. 

panelists 73

74 

neeRa Tanden 

President and CEO, Center for American Progress; Counselor, 

Center for American Progress Action Fund 

Neera Tanden is the president and CEO of the Center for American Progress. Most recently, 

Tanden served as the chief operating officer for the center. Tanden previously was senior 

advisor for health reform at the Department of Health and Human Services, advising Secretary 

Sebelius and working on President Obama’s health reform team to develop and pass the 

Affordable Care Act. Prior to that, Tanden was the director of domestic policy for the Obama- 

Biden campaign, managing all domestic policy proposals. Tanden served as policy director for 

the Hillary Clinton presidential campaign and associate director for domestic policy and senior 

advisor to the first lady in the Clinton administration. 

RusseLL TeagaRden 

Former Vice President, Scientific Affairs, Advanced Clinical Science & Research, 

Medco Health Solutions, Inc. 

J. Russell Teagarden most recently served as vice president of scientific affairs, and before that 

as vice president of clinical practices & therapeutics at Medco Health Solutions, Inc. During his 

19 years at Medco, he was chiefly involved in drug technology assessment, coverage policy 

development, clinical programming development, clinical oversight, and clinical support 

for the company’s clients. Prior to joining Medco, he practiced as a clinical pharmacist in 

critical care and drug information. His formal education and training is in pharmacy, research 

methods, bioethics, and medical humanities, and he holds several faculty appointments and 

serves on many advisory boards.

sTeven TRegay 

Founder, President, and CEO, FORMA Therapeutics 

Prior to founding FORMA in 2008, Steven Tregay was a managing director for the Novartis 

Option Fund. He led the fund’s investments in small pharmaceutical companies. Prior to 

joining the venture group, he was the executive director and head of strategic alliances at 

the Novartis Institutes for BioMedical Research. He managed a team that was responsible 

for identification, negotiation, and management of collaborations for the oncology and 

ophthalmology disease areas and all the technology areas. Prior to Novartis, he had roles in 

business development. He received a doctorate and master of science in organic chemistry 

from Harvard University and a bachelor of science from Davidson College. 

JeFFRey TRenT 

President and Research Director, The Translational Genomics Research Institute 

Jeffrey Trent leads the Translational Genomics Research Institute (TGen). Trent’s previous faculty 

positions have included University of Arizona, University of Michigan, Johns Hopkins University, 

and Arizona State University. He is also a member of the Mayo Clinic Comprehensive Cancer 

Center, the American Association for Cancer Research, the American Association for the 

Advancement of Science, the American Society of Human Genetics, and the American Society 

of Clinical Oncology. He previously served as director of the Division of Intramural Research of 

the National Human Genome Research Institute at the National Institutes of Health. 

panelists 75

76 

sean Tunis 

Director, Center for Medical Technology Policy 

Sean Tunis is the director of the Center for Medical Technology Policy (CMTP). In his role, 

he works with leading figures from the domestic and international healthcare industry on 

the development of new research methods designed to maximize the effectiveness of future 

medical technologies. Tunis founded the CMTP in 2006 after spending five years as the chief 

medical officer and director of the Office of Clinical Standards and Quality for the Centers for 

Medicare and Medicaid Services. Tunis received his medical degree and master’s degree from 

Stanford University and his bachelor’s degree from Cornell University. 

ROBeRT uRBan 

Head, Cambridge Innovation Center, Johnson & Johnson 

Robert Urban recently joined Johnson & Johnson’s Corporate Office of Science and Technology 

Policy. Prior to J&J, Urban was the executive director of the David H. Koch Institute for 

Integrative Cancer Research at MIT. At MIT, Urban’s primary goal was to make the institute 

the gold standard in interdisciplinary disease-focused research via an expanding, highlyeffective, 

relationship network with other academic oncology centers, industrial partners, 

and cancer-focused foundations. Before coming to MIT in 2007, Urban was involved in several 

start-up biotechnology companies and served in numerous leadership roles, ranging from 

overseeing infectious disease and oncology drug development programs, to developing new 

technologies, to running organizations as CEO. Urban received both an undergraduate and a 

doctoral degree from the University of Texas system.

dennis uRBaniak 

Vice President, U.S. Diabetes, Sanofi 

Dennis Urbaniak is vice president, U.S. Diabetes, for Sanofi, where he currently is responsible 

for the U.S. business unit operations for diabetes products and services and also serves as 

a member of the leadership team for the Sanofi global diabetes division. Prior to this role, 

Urbaniak has held positions such as the vice president of Innovation and New Customer 

Channels and vice president US Lovenox Marketing. He joined Sanofi in 1994 and has held 

various positions within marketing, sales operations, sales management, and sales. Urbaniak 

also serves as a member of the Monmouth University School of Science Advisory Council, 

chairman of the executive council for the Center for Healthcare Innovation, a senior fellow 

for the Jefferson School of Public Health, a member of the U.S. Chamber of Commerce 

Telecommunications and E-Commerce Committee, and a member of the Med Ad News 

editorial board. 

ChRis vaRMa 

President and CEO, Blueprint Medicines 

Chris Varma is president, CEO, and a co-founder of Blueprint Medicines at Third Rock Ventures, 

a Boston-based life sciences venture capital firm. He joined the firm in 2010 to develop 

and build new companies as an entrepreneur-in-residence, including recently Warp Drive 

Bio. Prior to Third Rock, Varma was a partner at Flagship Ventures, focusing on life sciences 

investments. Before Flagship, he oversaw clinical development, business development, 

and sales and marketing efforts at Novartis AG. Previously he was a consultant for Millennium 

Pharmaceuticals and worked for the Food and Drug Administration. Varma has a doctorate 

in biomedical engineering from the Harvard-MIT Division of Health Sciences and Technology, 

a master of science in management from Stanford University, and master and bachelor of 

science degrees in computer science from Stanford University. 

panelists 77

78 

MaTThias vOn heRRaTh 

Director, Type 1 Diabetes Research and Development (R&D) Center, Novo Nordisk 

Matthias von Herrath serves as director of the Center for Type 1 Diabetes R&D Center. His research 

focuses on strategies to prevent type 1 diabetes through the induction of regulatory T cells. 

His laboratory is collaborating with a major diabetes consortium in the U.S. and Australia, 

supported in part by the Juvenile Diabetes Research Foundation, to study the introduction 

of immune response modifiers to get the immune system back on track. Von Herrath also 

holds faculty positions at La Jolla Institute for Allergy and Immunology and the University of 

California. He also serves as president of both the Immunology of Diabetes Society and the 

Clinical Immunology Society. He is the 2008 winner of the American Diabetes Association 

Outstanding Scientific Achievement Award. He holds a medical degree from the Freiburg 

School in Freiburg, Germany. 

geORge vRadenBuRg 

Chairman, USAgainstAlzheimer’s 

George Vradenburg is the chairman and co-founder of USAgainstAlzheimer’s. Through this 

work, Vradenburg brought together stakeholders in the Alzheimer’s community as a 

co-convener of Leaders Engaged on Alzheimer’s Disease. He has testified before Congress 

about the global Alzheimer’s pandemic and was named by Secretary Sebelius to serve on the 

National Alzheimer’s Advisory Council. Additionally, he chairs the Vradenburg Foundation. 

Vradenberg previously served in senior positions at AOL/Time Warner, CBS, and Fox. He is 

also active in the Washington, DC community, serving on the boards of several organizations. 

Vradenburg received his bachelor of arts from Oberlin College and his law degree from 

Harvard Law School.

JOhn WiLBanks 

Senior Fellow, Ewing Marion Kauffman Foundation 

John Wilbanks is a senior fellow at the Ewing Marion Kauffman Foundation and runs the 

Consent to Research Project. From 1994 to 1997, he worked in Washington, DC, as a legislative 

aide to Congressman Fortney “Pete” Stark. After this, Wilbanks became the Berkman Center 

for Internet & Society’s first assistant director from the fall of 1998 to the summer of 2000. 

While at the Berkman Center, Wilbanks founded Incellico, Inc., a bioinformatics company 

that built semantic graph networks for use in pharmaceutical research and development. 

In 2004, Wilbanks became vice president of science at Creative Commons. In this role, he ran 

the Science Commons project throughout its duration. He frequently campaigns for wider 

adoption of open access publishing in science and the increased sharing of data by scientists. 

Wilbanks received his bachelor of arts in philosophy from Tulane University. 

aLasTaiR J.J. WOOd 

Partner, Symphony Capital 

Alastair Wood is a partner at Symphony Capital. He is also currently a professor of medicine 

and a professor of pharmacology (courtesy appointment) at Weill Cornell Medical School. 

He previously served more than 30 years at Vanderbilt University School of Medicine, most 

recently as associate dean of external affairs, where he was also an attending physician and 

a tenured professor of medicine and pharmacology. He was also the chairman of the FDA’s 

Nonprescription Drugs Advisory Committee and the FDA Advisory Committee on Cox-2 

inhibitors. Additionally, he served as a member of the Cardiovascular and Renal Advisory 

Committee of the FDA. Wood has been a member of and chaired National Institutes of 

Health study sections, served on the editorial boards of four major journals, and was the 

drug therapy editor of The New England Journal of Medicine. Most recently, he was named 

to the board of the Critical Path Institute. Wood has won numerous honors, including 

election to the National Academy of Sciences’ Institute of Medicine. He earned his medical 

degree at the University of St. Andrews. 

panelists 79

80 

JaneT WOOdCOCk 

Director, Center for Drug Evaluation and Research, U.S. Food and Drug Administration 

Janet Woodcock is the director of the Center for Drug Evaluation and Research at the Food 

and Drug Administration (FDA). Woodcock began working with FDA in 1986 and has also 

served FDA in roles as deputy commissioner and chief medical officer, deputy commissioner 

for operations, and chief operating officer. In these roles, she oversaw scientific and medical 

regulatory operations. She previously held other positions at FDA, including director, Office of 

Therapeutics Research and Review, and acting deputy director, Center for Biologics Evaluation 

and Research. Woodcock received a medical degree from Northwestern Medical School 

and completed further training and held teaching appointments at the Pennsylvania State 

University and the University of California, San Francisco.

expert 

consultations

82 

experts will provide pro bono issue analysis and tailored feedback 

based on participants’ specific needs and challenges, and will be 

available through the partnering system, P4c connect. 

STrATEgiC pLANNiNg 

These consultations will address strategic and business model issues, including establishing planning guidelines and 

timelines, conducting strategic analysis and organizational assessments, setting or changing strategic direction, refining 

goals and methods, approaching collaborations (with both partners and funders), and mapping/measuring success. 

RUssELL L. BROmLEy 

Principal 

TRAC Consulting 

In 2010, Russell L. “Rusty” Bromley formed TRAC Consulting to assist nonprofit medical research 

organizations in Translational Research Acceleration via Collaboration (TRAC). TRAC Consulting 

specializes in designing and implementing strategic research plans and collaborative 

operational models that are aligned with an organization’s mission and the unmet medical 

needs of patients. Prior to founding TRAC Consulting, he served for seven years as the chief 

operating officer of the Myelin Repair Foundation (MRF), where he was instrumental in the 

creation, implementation, and evolution of the MRF Accelerated Research Collaboration model. His principal 

responsibilities included development and execution of the MRF research plan, identification and protection of 

resulting intellectual property, and development of relationships with a broad range of academic and commercial 

organizations. Bromley brings a unique combination of business experience in both academic and commercial 

research environments. He has served as CEO of LabVelocity, Inc., an Internet information portal for the life science 

research community; CEO of Berkshire Holding Corporation, a privately held, multinational manufacturer of supplies 

for microelectronics and pharmaceutical production; and spent 17 years with American Hospital Supply Corporation 

and Baxter Healthcare. Bromley has a degree in biochemistry from Rice University.

LIz HORN 

Principal 

Liz Horn Consulting, LLC 

Liz Horn has spent her career building research initiatives and collaborations with patient and 

physician organizations, with a focus on registries and biobanks. She has worked in a variety 

of national and international organizational structures and formed her consulting practice 

in 2007 to focus on priority issues. Horn has a broad skill set that complements Partnering 

for Cures’ Expert Consultations. She is trained in both quantitative and qualitative methods, 

and has conducted focus groups, consensus exercises, and various surveys, including a 

national survey panel. She has facilitated numerous round-table consensus exercises with physicians to develop 

expert opinion on clinical decision-making. She has developed educational and training materials for medical 

professionals and consumers, breaking down complex scientific concepts. She recently developed a suite of tools 

with Genetic Alliance for individuals establishing or managing registries or biobanks. Her current research interests 

focus on exploring network interactions between providers, developing citizen scientist-driven research initiatives, 

understanding the psychosocial issues of dermatologic conditions, and cultivating non-traditional research 

collaborations. She earned her doctorate in molecular pharmacology and cancer therapeutics from SUNY at Buffalo. 

She was a National Library of Medicine fellow in biomedical informatics and received her M.B.I. from Oregon Health 

& Science University. 

DEBRA R. LAPPIN 

Senior Vice President 

FaegreBD Consulting 

Debra Lappin is recognized across government, academic, and nonprofit sectors as a 

leading strategist in public health and science policy. She brings expertise on innovative 

public-private partnerships, global consortia, and other strategic alliances among academic 

research institutions, voluntary health agencies, government, and industry. As former national 

chair of the Arthritis Foundation, Lappin is a recognized national spokesperson on public 

engagement in the nation’s public health and scientific enterprise. Lappin’s practice focuses 

on the changing roles of academia research institutions and the increasing influence of venture philanthropic patient 

organizations in accelerating translational research. She has led major science policy campaigns calling for public 

access to scientific communications and genetic non-discrimination. Lappin advises on the development of a broad 

range of emerging, complex tools to enable translation, such as disease registries, large integrated databases, biospecimen 

repositories, and cross-institution affiliations. Lappin has served as an advisor to the Centers for Disease 

Control and Prevention and the National Institutes of Health and has participated on a number of committees at the 

National Academy of Sciences. Lappin is president of the Council for American Medical Innovation, a member of the 

board of Research!America, and an adjunct professor at the University of Colorado Health Sciences Center. 

expert consultations 83

84 

PAUL L. ROsENBERg 

Partner 

Bridgespan Group 

Paul Rosenberg is a partner in The Bridgespan Group’s Boston office. He leads teams developing 

strategies for organizations focusing on public health, education, and disadvantaged 

populations, with a particular focus on advocacy and the intersection of the nonprofit and 

government sectors. He leads the firm’s public health focus area. He joined Bridgespan 

after 12 years at Bain & Company, where he was a partner and one of the leaders of the 

North American Health Care practice, working on issues of strategy, organization, and operations for companies in 

pharmaceuticals, medical devices, biotechnology, health insurers, and providers. Rosenberg co-authored Bain’s work 

on “Innovation Imbalance,” which was featured at the World Economics Forum’s Davos gathering and published in 

The Economist and In Vivo. He also led a team exploring the public policy implications of Canadian drug regulatory 

and pricing policies. Rosenberg is currently a member of the Advisory Committee of the MAPS Adoption and 

Humanitarian Aid Organization, the Dean’s Advisory Board of the Boston University School of Public Health, and 

the Board of Advisers of The Harvard Law School Public Service Venture Fund. Rosenberg is a graduate of Harvard 

College, Harvard Law School, and Harvard Business School. 

mARIE scHILLER 

Partner 

Health Advances 

Marie Schiller is a partner at Health Advances, a consulting firm specializing in the 

commercialization of new healthcare technologies. Her clients range from start-ups to 

pharmaceutical/medtech companies to nonprofit disease organizations. Schiller has worked 

with her clients, many for more than 10 years, on critical commercial decisions including 

asset acquisitions, product launch/lifecycle strategy, and franchise planning. The depth and 

breadth of her knowledge across the healthcare industry brings a unique competitive advantage to her clients. 

Schiller’s consulting career started as a generalist with expertise in drug delivery and protein therapeutics. Over the 

years, she has focused on metabolic diseases and now runs Health Advances’ metabolic practice. She is considered 

one the country’s most formidable diabetes experts. Her interest in diabetes is driven in large part by her personal 

27-year history living with type 1. Over the past five years, Schiller has had the opportunity to bring her consulting 

experience to nonprofit organizations. Recently, she took a sabbatical to oversee the development of a diabetes 

exchange being funded by the Helmsley Trust. Prior to joining Health Advances, Schiller worked in research and 

commercial planning at ArQule and Gel Sciences. She graduated from the University of Vermont with a bachelor 

of arts in chemistry.

cAROLyN vAN DAmmE 

President and Founder 

The Round Peg Group 

Carolyn Van Damme is the president and founder of The Round Peg Group, an innovative, 

woman-owned boutique consulting company serving the Washington, DC area. Her clients 

include government agencies and nonprofit, education, and healthcare organizations, as well 

as Fortune 500 companies and new start-ups. Trained as an engineer, she brings fresh thinking 

and innovative, practical client solutions in the areas of strategic and business planning, 

project management, and marketing and communications. Van Damme has worked for the high-tech industry, 

a think tank, an industry nonprofit, two start-ups, and the government. Prior to founding Round Peg, Van Damme 

served as the acting vice president at the Potomac Institute for Policy Studies, responsible for business development 

and a portfolio of federal contracts for agencies as diverse as the National Science Foundation, the Office of Naval 

Research, the Defense Advanced Research Projects Agency, and the Office of Science and Technology Policy. 

Van Damme’s experience includes working for the U.S. Commerce Department’s Advanced Technology Program, 

Infotech Strategies, the Computer Systems Policy Project, Podesta Associates, and the Council on Competitiveness. 

She started her career as a field engineer with Schlumberger and Contel Cellular. Van Damme received degrees in 

public policy and industrial engineering from the Georgia Institute of Technology. 


86 

COLLABOrATiON STrUCTUriNg 

These consultations will address various methods for formalizing and carrying out cross-sector partnerships 

as efficiently and effectively as possible. This category covers issues such as intellectual property, data sharing, 

and conflicts of interest to ensure that the proper legal and structural agreements/policies/processes are in place 

for successful collaborations. 

BETH E. ARNOLD 

Partner 

Foley Hoag LLC 

Beth E. Arnold, a partner in Foley Hoag LLP’s intellectual property practice, is a U.S. registered 

patent attorney with 25 years of experience in obtaining worldwide patent protection for 

pharmaceutical and biotechnology products. Her clients include top-tier pharmaceutical 

companies, public and private biotechnology companies, and medical research institutes. 

In addition to obtaining patents, Arnold prepares and negotiates agreements for developing 

and commercializing new products and technologies. She also performs patent due diligence 

in connection with financings, mergers, acquisitions, and other business combinations. She also provides noninfringement 

and invalidity opinions. An experienced player in the life sciences field, Arnold served as in-house 

patent counsel at Genzyme Corporation in the mid-’90s and as a technology transfer officer at the Massachusetts 

General Hospital. Arnold consistently receives recognition as a leading IP practitioner from Chambers USA, The Best 

Lawyers in America, Massachusetts SuperLawyers, and Global Counsel 3000. 

mARK E. BOULDINg 

Executive Vice President & Chief Legal Officer 

PTC Therapeutics 

Mark Boulding is the executive vice president and chief legal officer of PTC Therapeutics, Inc., 

a privately held biopharmaceutical company located in South Plainfield, NJ. His responsibilities 

include negotiation of licensing arrangements, business development transactions, and grant 

agreements; interactions with the government and universities on technology transfer and 

contracting matters; management of PTC’s intellectual property portfolio; and management 

of the finance, legal, quality assurance, regulatory, and human resources departments. 

PTC has a strong track record of drug discovery and development collaborations with nonprofit and government 

entities, including the Spinal Muscular Atrophy Foundation, the Parent Project Muscular Dystrophy, the Wellcome 

Trust, Cystic Fibrosis Foundation Therapeutics, and the Muscular Dystrophy Association, and Boulding has been the 

lead negotiator for those collaborations. Prior to working for PTC, Boulding was the general counsel and executive 

vice president, Government and Regulatory Affairs, of MedicaLogic/Medscape, Inc., a publicly traded company offering 

healthcare software and information products to physicians and consumers. Before Medscape, Boulding was a law firm 

partner in private practice in Washington, DC, specializing in healthcare and technology law, with a focus on pharmaceutical, 

biotech, and high-tech companies. He is a member and past chair of the BIO General Counsels’ Committee.

DAvID LUBITz 

Partner 

Schaner & Lubitz, PLLC 

David Lubitz is a partner in Schaner & Lubitz, PLLC (www.schanerlaw.com), a law firm that 

specializes in providing outside general counsel services to disease foundations and helping 

them invest in scientific innovation leading to cures and therapies. Lubitz has been practicing 

law for 20 years. He serves as counsel to or has advised the Cystic Fibrosis Foundation and its 

affiliates, the American Clean Skies Foundation, Global Impact, The Michael J. Fox Foundation 

for Parkinson’s Research, the Helmsley Charitable Foundation, the Juvenile Diabetes Research Foundation, the Simons 

Foundation, the National Neurovision Research Institute, the Cancer Research Institute, the Tau Consortium, and other 

501(c)(3) tax-exempt organizations. Lubitz was a law partner at two firms in Washington, DC, Swidler Berlin and Bingham 

McCutchen, before forming Schaner & Lubitz. He is a graduate of the Columbia Law School and Harvard College. 

TERI mELEsE 

Professor, Department of Medicine, and Director, Business Strategy and Development 

School of Medicine, University of California, San Francisco 

Teri Melese is a professor in the Department of Medicine at the University of California, 

San Francisco (UCSF) and is the director of Business Strategy and Development for the 

School of Medicine. In this position, she works with institute and center directors, as well as 

individual faculty, and life science companies to craft and implement research collaborations. 

She is on the Executive Leadership Team of the Helen Diller Family Comprehensive Cancer 

Center. Melese has published a number of articles in high-impact journals on the nature of effective academic/ 

industry partnerships. Before joining UCSF in 2001, she ran an independent research laboratory in yeast genetics 

and molecular biology at Columbia University from 1988 to 1997, where she was awarded the prestigious National 

Science Foundation Young Presidential Investigator Award. In 1997, she left Columbia to be founding member of 

a venture-backed start-up company, Iconix Biosciences (acquired by Entelos), in Silicon Valley. She has four patents 

for biomedical technologies and small molecule inhibitors. Melese holds an A.B. from the University of California, 

Berkeley, a Ph.D. in cell biology from UCSF (Regents Fellow), and was an American Cancer Senior Postdoctoral 

Fellow at the University of California, Los Angeles. 


88 

LILI m. PORTILLA 

Acting Director 

Office of Policy, Communications and Strategic Alliances, National Center for Advancing 

Translational Sciences 

Lili Portilla has worked in the area of technology transfer at the National Institutes of Health (NIH) 

since 1989. She has extensive experience in negotiating and developing commercialization 

strategies for complex and multi-party collaborations and public-private partnerships. 

Portilla has broad knowledge of federal and NIH technology transfer policy and law pertaining 

to biotechnology and commercialization issues. Portilla was recently named the acting 

director of the Office of Policy, Communications and Strategic Alliances at the newly formed National Center for 

Advancing Translational Sciences (NCATS) at the NIH. Portilla currently serves as the director of the Office of Strategic 

Alliances for NCATS. From January 2008 until 2011, Portilla served as senior advisor to the director of the National 

Center for Research Resources (NCRR) and provided advice to NCRR staff on all facets of technology transfer, 

intellectual property, and public-private partnerships issues. Prior to NCRR, Portilla served for seven years as the 

director of the National Heart, Lung and Blood Institute, Office of Technology Transfer and Development. 

Portilla received a master of public administration in 1992 from American University and a bachelor’s degree 

in business administration from Stephen F. Austin State University. 

KEN scHANER 

Managing Partner 

Schaner & Lubitz, PLLC 

Ken Schaner is managing partner of Schaner & Lubitz, PLLC, where he has represented many 

for-profit and nonprofit entities in the corporate and tax aspects of a wide variety of agreements, 

transactions, financings, licenses, mergers, and acquisitions. Schaner serves as general and 

outside counsel to many nonprofits and has represented the Cystic Fibrosis Foundation, Juvenile 

Diabetes Research Foundation, Stanley Medical Research Institute, National Neurovision Research 

Institute, National Multiple Sclerosis Society, and others in numerous venture philanthropy 

transactions and related legal matters. Schaner began his career at the Internal Revenue Service’s legislative and 

regulations division. He holds a bachelor’s degree and J.D. from the University of Illinois.

mARK scHEIDELER 

Founder 

Human First Therapeutics LLC 

Mark Scheideler founded HumanFirst Therapeutics LLC to provide consulting and managing 

partner expertise to groups seeking to form, fund, and operationally manage life science 

projects that move therapeutic opportunities forward to clinical development. Clients have 

included universities and disease foundations seeking to progress potential therapies, 

and companies pursuing Federal SBIR, contract, and grant funding for therapies, enabling 

technologies, and services. Prior to starting the LLC, Scheideler served as a senior scientific 

officer at the NIH from 2005 to 2011, working with translational research initiatives spanning the 27 institutes and 

centers. He came to the NIH with 14 years of international pharmaceutical and biotechnology R&D experience. 

Key assignments included senior executive posts at MDS Proteomics, SmithKline Beecham (and GlaxoSmithKline), 

and Novo Nordisk Healthcare. Scheideler has held academic posts as research assistant professor at Albert Einstein 

College of Medicine, and postdoctoral fellow at Duke University Medical Center. He completed a Ph.D. in biochemistry 

at The University of Chicago, a bachelor of arts in biochemistry & molecular biology at Northwestern University, 

and a certificate in finance & accounting at The Wharton School of Business. 

scOTT J. WEIR 

Director, Institute for Advancing Medical Innovation 

University of Kansas Cancer Center 

Scott J. Weir is director, Institute for Advancing Medical Innovation (IAMI), University of 

Kansas. IAMI conducts development-focused translational research on products with clear 

paths to market. He also serves as associate director, translational research at the University 

of Kansas Cancer Center. Drugs, diagnostics, and medical device applications in cancer, 

neuroscience, and rare and neglected diseases, in children and adults, are the primary 

focus of IAMI. Central to IAMI’s strategy is establishing and executing projects through highperformance 

collaborations with industry, academia, government, and disease philanthropy organizations. 

Weir has over 26 years of professional experience in the field of drug discovery and development, 20 of which 

were spent in the pharmaceutical industry prior to joining the University of Kansas in 2006. His areas of expertise 

are in clinical pharmacology, pharmacokinetics, biopharmaceutics, and developing innovative approaches to lead 

optimization and early drug development. He has built a reputation of being innovative in bridging the “Valley of 

Death” through high-performance public-private partnerships as well as repurposing approved drugs and rescuing 

abandoned drugs. In 2012, Weir was appointed by HHS Secretary Kathleen Sebelius to serve on the National Center 

for Advancing Translational Sciences Advisory Council as well as the Cures Acceleration Network Board. 


90 

ATTrACTiNg CApiTAL 

These consultations will focus on funding. Consultants will come from both the foundation and investor perspectives 

and will provide best practices and guidance around the strategic acquisition and allocation of capital (i.e., evaluating 

philanthropic investment, building a high-impact medical portfolio, attracting investors, resource-building, etc.). 

cHRIsTOPHER EARL 

President 

Innotrove LLC 

Christopher D. Earl is an entrepreneur, investor, and nonprofit leader with broad experience 

in science, venture capital, and the management of biotechnology companies and nonprofit 

organizations. He serves as senior advisor to the Merck Global Health Innovation venture 

capital fund, and through Innotrove LLC advises other leading biopharma companies. 

Previously, Earl was the first president and CEO of BIO Ventures for Global Health (BVGH), 

a nonprofit organization devoted to harnessing biotech R&D to develop cures for neglected 

tropical diseases. Supported by industry and the Bill & Melinda Gates Foundation, BVGH promoted financial 

incentives for tropical disease R&D and forged collaborations between leading companies and research institutions. 

Earl joined Perseus Capital in 1997 to build its investment portfolio in biotechnology and launched the Perseus-Soros 

BioPharmaceutical Fund. He led investments in companies developing therapeutics for oncology and infectious 

diseases, and served as a director on portfolio company boards. Several of these companies achieved FDA approval 

for innovative drugs that today sell over $1 billion. Earl serves on the boards of Daktari Diagnostics, Asuragen, and 

Mirna Therapeutics. He is a trustee of the Nature Conservancy of Maryland/DC. Earl received his PhD in cellular and 

developmental biology from Harvard University. 

DAvID sTEINBERg 

Partner 

PureTech Ventures 

David Steinberg is a partner at PureTech Ventures. As a member of PureTech, Steinberg has 

served as founding CEO and board member of portfolio companies Enlight Biosciences, 

Endra Inc., Vedanta Biosciences, Entrega Biosciences, and Knode Inc. He also served as 

chief business officer of portfolio company Follica, Inc., and vice president of operations for 

portfolio company Satori Pharmaceuticals. Previously, he was a strategy consultant with 

the Boston Consulting Group and Vertex Partners, focusing on R&D, product strategy, and 

strategic alliances for Fortune 500 pharmaceutical and biotechnology clients. Steinberg also worked as a research 

associate in Procter & Gamble Pharmaceuticals’ R&D organization. He received his bachelor of arts in biology with 

distinction from Cornell University and graduated with high honors from the University of Chicago Booth School 

of Business with a master of business administration in strategy and finance. Steinberg is also a member of the 

UChicago Tech Innovation Fund Advisory Committee.

cHRIs vARmA 

President and CEO 

Blueprint Medicines 

Chris Varma is president, CEO, and a co-founder of Blueprint Medicines at Third Rock Ventures, 

a Boston-based life sciences venture capital firm. He joined the firm in 2010 to develop and 

build new companies as an entrepreneur-in-residence, including recently Warp Drive Bio. 

Prior to Third Rock, Varma was a partner at Flagship Ventures focusing on life science 

investments. While at Flagship, he served as the president, CEO, and director of Selventa, Inc., 

where he led a rapid and profitable turnaround. Before joining Flagship, he oversaw efforts 

spanning clinical development, business development, and sales and marketing at Novartis AG. Most recently, 

Varma was director on Tekturna (aliskiren), where he led key aspects of its U.S. commercial launch, including 

marketing, regulatory, and reimbursement activities. Prior to Novartis, he was a consultant for Millennium 

Pharmaceuticals and has worked for the U.S. Food and Drug Administration. Varma holds a Ph.D. in biomedical 

sciences from the Harvard-MIT Division of Health Sciences & Technology, a master of science in management from 

Stanford University, and both a master of science and a bachelor of science in computer science from Stanford 

University. Varma serves as a member of the Harvard Medical School Therapeutics Advisory Council and as a 

leadership board member of The McGovern Institute for Brain Research at MIT. 

gREgORy m. WEINHOff 

Partner 

CHL Medical Partners 

Greg Weinhoff is active in the biotechnology, molecular diagnostics, medical device, 

and healthcare services sectors. He was the founding CEO of Amicus Therapeutics, Inc., 

where he played a key role in identifying and licensing the technology platform, hiring the 

management team, and developing the company’s strategic plan. He also served as President 

of VaxInnate Corporation during its early development and is currently executive chairman at 

Resolvyx Pharmaceuticals, Inc. More recently, Weinhoff was a co-founder of Ella Health, Inc. Weinhoff also serves on 

the IAVI Innovation Fund Venture Advisory Committee. Prior to joining CHL Medical Partners in 2001, Weinhoff was 

a senior associate at Whitney & Co. Earlier in his career, Weinhoff was with the healthcare Corporate Finance Group 

at Morgan Stanley & Co. where he worked on financings and merger and acquisition assignments for a number of 

biotechnology, pharmaceutical and healthcare services clients. Weinhoff is a graduate of Harvard College, 

Harvard Medical School, and Harvard Business School, where he was a Baker Scholar. 


92 

iNTErACTiNg wiTh ThE FdA 

These consultations will address how to interact with FDA around various points of interest (biomarker validation, 

data collection guidelines, IND/NDA tracking, clinical trial protocols, communication with industry, etc.). 

These sessions will feature consultants who can offer advice on what to expect from the regulatory review process 

and where to go for unique issues/challenges. 

ENRIqUE AvILés 

Chief Technology Officer 

C-Path 

Enrique Aviles has more than 30 years of experience in data storage, information technology 

product development, and program management, and has led numerous projects to 

support large IT clients with a special focus on healthcare and banking IT systems. Prior to 

joining C-Path in 2010, his executive roles at IBM included data storage product program 

management, storage product development, client technical support, and marketing. 

His executive experience also includes a two-year assignment working as the IBM technical 

advocate for Kaiser Permanente in support of Kaiser’s HealthConnect® electronic health records system, one of the 

largest deployments of an electronic health records system. In this role, his responsibility was to ensure that IBM 

hardware, software, and services used for HealthConnect® operated reliably on a 7x24 basis. Additionally, Aviles 

was the IBM executive data storage advocate for one of the largest banks in Japan (Bank of Tokyo-Mitsubishi UFJ) 

and traveled to Japan several times a year to review product quality and new product development status with 

the bank’s senior executives. Aviles received his bachelor of science in mechanical engineering from the Georgia 

Institute of Technology. He also received graduate certificates from the University of Arizona for an executive MBA 

program and from George Washington University for project management. 

mIcHAEL c. BEcKLOff 

President 

Beckloff Associates 

Michael C. Beckloff is president of Beckloff Associates, Inc. (BAI), a Cardinal Health Company. 

Beckloff has more than 30 years of experience with global drug development and regulatory 

affairs. BAI assists pharmaceutical and biotechnology clients in bringing new has more than 

30 years of experience with global drug development and regulatory affairs. They have 

successfully supported worldwide drug development across a broad range of therapeutic 

categories and have worked with virtually all types of product formulations. Beckloff earned 

his bachelor’s degree in cellular biology from the University of Kansas.

ELIzABETH mOyER 

CEO 

M/P Biomedical Consultants 

Elizabeth D. Moyer is the CEO of M/P Biomedical Consultants LLC (M/P LLC). She was 

formerly senior vice president of product development and operations at Kinetek 

Pharmaceuticals Inc. and director of preclinical development at Athena Neurosciences/ 

Elan Pharmaceuticals. M/P LLC advises and assists startup and multinational biomedical, 

biotechnology, and pharmaceutical companies, venture capitalists, and university translational 

granting programs in a variety of classes of drugs, from small molecules to protein drugs, 

in a wide range of therapeutic areas, including neurology, dermatology, cardiovascular, oncology, endocrinology, 

ophthalmology, and gastroenterology. As part of this consulting business, Moyer has helped companies, academics, 

and nonprofit organizations to tailor their research path to optimizing a successful path forward with regulatory 

agencies. Moyer has extensive experience directing all phases of pharmaceutical product development, including 

preclinical and clinical development, parenteral and ophthalmic drug formulation, CMC, and regulatory affairs. 

Moyer obtained a doctorate in biochemistry from SUNY Buffalo and conducted postdoctoral studies at SUNY Buffalo 

and Johns Hopkins University School of Medicine. 

mARc WILENzIcK 

Life Sciences/FDA Attorney; Senior Advisor 

Harvard Multi-Regional Clinical Trial Center 

Marc Wilenzick is an attorney in private practice with expertise in FDA strategy, regulatory 

law, and R&D. He currently serves as the senior advisor to Harvard’s Multi-Regional Clinical 

Trial Center and as the co-chair of the regulatory working group for New York’s Partnership 

to Advance Clinical Electronic Research (PACeR) involving medical centers, health systems, 

community hospitals, patient representatives, pharmaceutical companies, health information 

technology companies, and others. Wilenzick was with Pfizer for 15 years, serving as the 

chief compliance counsel for R&D and as an assistant general responsible for Clinical Trial Policy & Regulatory Law. 

In addition, while at Pfizer, Wilenzick served as the lead attorney for the Specialty Portfolio, covering the Cancer, 

Ophthalmology, Anti-infective, Endocrine & Diversified Products, and as the brand counsel to numerous product 

teams. Before Pfizer, Wilenzick served as an assistant chief counsel at the U.S. Food and Drug Administration and was 

an enforcement attorney with the Federal Trade Commission. Wilenzick is a graduate of the University of Texas at 

Austin, where he received a bachelor of arts, cum laude, and a law degree. He is a member of the New York, Georgia, 

and District of Columbia Bars. 


94 

COmmUNiCATiONS ANd mArkETiNg 

These consultations will focus on building visibility and credibility with collaborators and media, strategies for 

evaluating and pursuing thought leadership opportunities and collaborators, and promoting strengths, successes, 

and unique attributes of organizations/projects to potential partners and funders. 

BARBARA LAvERy 

President 

Zoomedia 

Barbara Lavery is responsible for Zoomedia’s continuing leadership in life science 

communications, developing innovative marketing, branding, and communications 

programs that combine traditional and new media expertise. During her 13-year tenure at 

Zoomedia, she has built the Zoomedia brand and client base and has become a recognized 

life science communications expert, creating and implementing numerous successful online 

campaigns for leading companies and nonprofit organizations. Lavery’s client experience 

spans pharmaceutical companies, disease research organizations and venture capital groups including Novo Nordisk, 

Gilead, Celgene, the Love/Avon Army of Women, the Epilepsy Therapy Project, the Parkinson’s Disease Foundation, 

TPG Biotech, and Burrill & Company. Prior to joining Zoomedia, Lavery had a successful career as a stage production 

designer, including a five-year stint at the Abbey Theater in Dublin. She graduated with honors from Central St. 

Martins College of Art in London. 

sALLy sqUIREs 

Senior Vice President 

Powell Tate 

Sally Squires is director of Health and Wellness Communications. She specializes in the design 

and implementation of nutrition, food, and health advocacy programs for government, 

nonprofit, and corporate clients. Before joining Powell Tate in 2008, Squires was an awardwinning 

nationally syndicated nutrition columnist and health writer for the Washington Post. 

Squires is also an author, a frequent contributor to many national magazines, and has 

co-produced and co-written a PBS documentary. She holds two master’s degrees in nutrition 

and in journalism, both from Columbia University.

mAUREEN L. sUDA 

Principal 

Suda Communications LLC 

Maureen Suda is a trusted communications executive with 20 years of experience providing 

innovative strategies and quantifiable business outcomes to organizations in the drug 

development, health science, and high-tech sectors. Suda’s strength lies in her ability to 

quickly translate complex information into a compelling story and then executing highly 

tailored communication programs that achieve reputation-enhancing public relations results. 

Since founding Suda Communications in 2004, she has focused on corporate positioning, 

awareness, and value-creation for startup companies. Suda previously led communications for the worldwide R&D 

organization at the Eastman Kodak Company during the company’s digital transformation. She held two positions 

at Millennium Pharmaceuticals, Inc., serving as associate director of public policy, supporting government relations 

activities for the company, and earlier directed public relations while serving as the media spokesperson. Suda began 

her consulting career at two New York-based public relations agencies - Burson-Marsteller and Chandler Chicco - 

where she supported communication programs for clients such as Pfizer, Searle, Bayer, Wyeth, Bristol-Myers Squibb, 

and Sanofi. She began her career at the Federation of American Hospitals in Washington, DC. She holds degrees from 

the University at Buffalo, the Bryce Harlow Institute of Business and Government Affairs at Georgetown University, 

and Boston University. 


sponsors

Benefactor 

THE LEONA M. A ND HARRY B. 

HELMSLEY 

C H A R I T A B L E T R U S T 

Leadership circLe 

GoLd 

siLVer 

sponsors 

97

LEARN MORE AT onyx.com 

We’re here 

for a reason. 

We’re here for a reason. 

................................................. 

To transform lives 

by transforming medicine. 

To transform lives by 

transforming medicine. 

At Onyx, this is the guiding principle 

that drives both our scientific innovation 

and our dedication to deliver novel therapies 

to patients with life-threatening diseases. 

At Onyx, this is the guiding 

principle that drives both 

our scientific innovation 

and our dedication to 

deliver novel therapies to 

patients with life-threatening 

diseases.

108 

SUppOrTErS

miLkEN iNSTiTUTE STrATEgiC pArTNErS 

strategic partners 

109

MILKEN INSTITUTE 

2013 

GLOBAL 

CONFERENCE 

ApriL 28 - mAy 1 

BEVErLy hiLTON 

LOS ANgELES 

www.globalconference.org

margaret Anderson 

Executive Director 

cecilia O. Arradaza 

Director, Communications & Marketing 

LaTese Briggs 

PAS Program Analyst 

Kathi E. Hanna 

Fellow 

Anika Khan 

Intern 

sarah Lengauer 

Intern 

susanna Ling 

Associate Director, Development 

samantha mayberry 

Program Assistant 

Joseph Ortega 

Operations Assistant 

gillian Parrish 

Manager, Outreach & Communications 

Karen Rogers 

Communications Manager 

Kristin schneeman 

Program Director 

Lisa simms 

External Affairs and Operations Director 

melissa stevens 

Deputy Executive Director 

Karlee stewart 

Communications Coordinator 

shawn sullivan 

Program Associate 

Elizabeth West 

Program Manager 

staFF 

111

112 

FasterCures would like to thank Milken Institute staff and fellows: 

India Allenby 

Executive Assistant 

martha Amram 

Senior Fellow 

Tracy Andreen 

Receptionist / Administrative Assistant 

Roubina Arakelian 

Executive Assistant to the President, 

CEO and COO 

Jason Barrett 

Digital Media Coordinator 

James R. Barth 

Senior Finance Fellow 

John Bartlett 

Senior Research Analyst 

melissa Bauman 

Editor 

Armen Bedroussian 

Senior Economist 

Bradley D. Belt 

Senior Managing Director 

michael Bernick 

Research Fellow 

Jared Bernstein 

Economic Policy Fellow 

Dale Bonner 

Senior Advisor 

melanie Bouer 


Angelo Bouselli 

Communications Director, 

Melanoma Research Alliance 

Julianne Brands 

Program Assistant 

Laura Brockway-Lunardi 

Scientific Program Director, 


chris Brummer 

Senior Fellow 

fran campione 


Alexandra carney 

Scientific Program Coordinator 

Jared carney 

Senior Fellow; Acting Director, 

Asia Center 

Ilyona carter 

Executive and Operations Manager, 


Nart charuworn 

Database Analyst 

Anusuya chatterjee 

Economist 

Ross c. Devol 

Chief Research Officer 

christopher Diaz 

Accounting Supervisor 

Richard Ditizio 

Executive Director, 

Program Development 

Jackson Dragon 

Senior Manager, 

Operations and Administration 

Alain Dudoit 

Visiting Fellow 

Dianna Dunne 

Director, Government Affairs 

Jennifer Engel 

Development Manager, 


William H. frey 

Senior Fellow 

Alma gadot-Perez 

Director, Israel Center 

Jie gan 


Ashley gerson 

Event Coordinator 

Karen giles 


Daniel gorfine 

Director of Special Projects; Legal Counsel 

Adam gottschalk 

Intern 

Priscilla Hamilton 

Research Analyst 

Kamyab Hashemi-Nejad 

Director of Finance 

muriel Hauser 


Jill Hoyt 

Associate Director, 

Development and Marketing 

michael D. Intriligator 

Senior Fellow 

Paul H. Irving 

Senior Managing Director and Chief 

Operating Officer 

zachary Karabell 

Senior Fellow 

conrad Kiechel 

Director of Communications 

Jaque King 


Kevin Klowden 

Director, California Center; 

Managing Economist 

michael L. Klowden 

President and CEO

Joel Kurtzman 

Senior Fellow; Executive Director, 

Center for Accelerating Energy Solutions 

Lauren c. Leiman 

Director of Marketing and Development, 


Ross Levine 

Senior Fellow 

Tong (cindy) Li 

Senior Economist 

stephen Lin 


yu (Lydia) Liu 


courtney Lyman 


caitlin macLean 

Senior Manager, 

Financial Innovations Labs 

Julee mccarthy 


Joe meehan 

Director, Database Marketing 

and Information 

michael milken 

Chairman 

clinton misamore 

Program Development Associate 

Kevin m. murphy 

Senior Fellow 

Joshua Nimmo 

Research Assistant 

Katie O’Reilly 

Associate Director, Marketing 

and Program Development 

Nancy Ozeas 

Associate Director of Programs 

Peter Passell 

Editor, The Milken Institute Review; 

Senior Fellow 

Tomas J. Philipson 

Senior Fellow 

Triphon Phumiwasana 


Apanard (Penny) Angkinand Prabha 

Economist 

Bryan quinan 

Associate Director, Events 

skip Rimer 

Executive Director of Programs 

and Communications 

sofia sami 

Event Relations Specialist 

sean sandbach 

Coordinator, Marketing and 


sarah sandler 

Associate, Marketing and 


Richard L. sandor 

Senior Fellow 

Keith savard 

Senior Managing Economist 

Wendy K.D. selig 

President and CEO, 


I-Ling shen 


mindy silverstein 

Managing Director, Marketing 


Jonathan simons 

Senior Fellow 

frank song 


Howard soule 

Senior Fellow 

Komal sri-Kumar 

Senior Fellow 

Trevor steele 

Coordinator, Social Media 

Phillip L. swagel 

Senior Fellow 

Erin Tanenbaum 

Manager, Program Development 

Robert H. Topel 

Senior Fellow 

Andrew c. von Eschenbach 

Senior Fellow 

Teresa Whang 


Heather Wickramarachi 


Ronnie Wiessbrod 

Development Coordinator 

Nevada Wolf 


michael Wolfe 


Perry Wong 

Director of Research 

Henry Woodside 

Database Manager, 


glenn yago 

Senior Director, Israel Center; 

Senior Research Fellow; and 

Founder, Financial Innovations Labs 

Elena zager 

Senior Associate, Marketing 


Khine zan 

Accountant 

Betsy zeidman 

Senior Fellow 

Allen zhang 

Accounting Manager 

Nan zhang 


Nan (Annie) zhang 

Research Intern 

staFF 

113

114 

ACkNOwLEdgmENTS 

FasterCures would like to thank the following companies for their service and support: 

milken family foundation 

Creative Services 

Event Production 

Execpro services 

Information Services 

Technical Support 

Jujama, Inc. 

Partnering Database Services 

Technical Support

NOTES

A social media campaign to demonstrate 

Why MedICaL reSearCh MatterS.

Because we must provide decision makers with a 

strong imperative to make research a national priority. 

Share your Story today. www.timeequalslives.org

WhO We ARe 

FasterCures is not just our name—it’s our mission. 

We are an “ActiOn tAnk” that works to improve the 

medical research system so that we can speed up 

the time it takes to get important new medicines 

from discovery to patients. 

WhAt We dO 

At FasterCures, we work to clear the path to faster 

progress by educating stakeholders about the barriers, 

and by overcoming them through action. We: 

• stimuLAte innOVAtiVe cOLLABORAtiOns 

across all sectors—academia, government, 

industry, investors, and nonprofits. 

• incReAse pAtient enGAGement 

in research and optimize use of patient data. 

• impROVe ReseARch pROcess & pOLicY 

to support efficient development and 

approval of new therapies. 

• FAciLitAte GReAteR Access And mORe 

stRAteGic ALLOcAtiOn OF cApitAL 

to support results-driven medical research.

1250 Fourth Street 

Santa Monica, CA 90401 

Phone: (310) 570-4600 

E-mail: info@milkeninstitute.org 

www.milkeninstitute.org 

1101 New York Ave. NW, Suite 620 

Washington, DC 20005 

Phone: (202) 336-8900 

E-mail: info@fastercures.org 

www.fastercures.org

Grand Hyatt Hotel, New York City 2012 | November 28-30

Create successful ePaper yourself

Delete template?

Save as template?